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Abstract 
Influenza A viruses are important pathogens that cause disease in a wide variety of 
species leading to economic losses and added burden on health care. Recently, outbreaks of 
avian influenza viruses in the human population have added to this growing risk of pandemic 
influenza viruses. Therefore, strategies to address the demands of higher efficiency, 
immunogenicity, and safety in influenza vaccines must be explored. One strategy which 
addresses efficiency and immunogenicity is to explore the addition of an adjuvant to influenza 
vaccines.  
Adjuvants are commonly used vaccine components which are included to induce a robust 
immune response leading to antigen sparing, a broader spectrum of protection and the 
elimination of a booster. Recently the retinoic acid-inducible gene-I (RIG-I) pathway, which is 
the natural defense against RNA viruses, has become an attractive target for adjuvant 
development. In this thesis, we sought to explore the possibility of a small RNA molecule, RNA-
LZ-1, identified in our laboratory as a RIG-I agonist as an adjuvant.  
This project evaluated the induction of pro-inflammatory cytokines, chemokines, and 
interferons by RNA-LZ-1 in vitro and in vivo, and tested its ability to induce antigen-specific 
antibodies when paired with H5N1 and H7N9 inactivated whole influenza viruses. We 
hypothesized that due to RNA-LZ-1’s binding affinity for RIG-I it will induce a broad spectrum 
immune response and fortified adaptive response when used as an adjuvant. Overall our results 
showed that RNA-LZ-1 was capable of inducing activation of a diverse spectrum of 
inflammatory genes and proteins in vitro and in vivo. In human macrophages and lung epithelial 
cells RNA-LZ-1 induced significant levels of IFN-β	protein	and	mRNA	fold	change.	We also 
showed that as early as 3 hours post-injection, RNA-LZ-1 was capable of up-regulating immune 
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genes with the effect dissipating by 48 hours post-injection. These immune genes were grouped 
as follows cytokines (IL-12α, IL-12β, IL-6, and IL-18), chemokines (MIP-1α, RANTES, MIP-2, 
MCP-1, and IP-10), and interferons (IFN-α, IFN-β, and IFN-ɣ). The overall immune response 
observed was skewed towards a Th1 response. In vivo, RNA-LZ-1 was able to induce protective 
antigen-specific antibodies against H5N1 in comparable levels to the proven VIDO triple 
adjuvant showing that RNA-LZ-1 is a strong candidate as an adjuvant for influenza vaccines.	
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Chapter 1 Introduction 
1.1 Influenza virus 
1.1.1 Genome and proteins 
Influenza A virus is part of the orthomyxoviridae family which is comprised of single-
stranded negative sense RNA viruses that do not develop long-term host-virus relationships, as 
the virus does not become dormant at any point in the life cycle (Jenigan & Cox, 2013). 
Influenza A viruses have a broad host range including humans, wild and domestic birds, swine, 
equine, canine, feline, and seals to name a few (Klenk, Garten, & Matrosovich, 2013). The 
genome consists of eight segments, encoding for both structural and non-structural proteins, 
which are numbered one through eight by decreasing length (Bouvier & Palese, 2008). These 
segments are located in the virus core and are enveloped by matrix protein (M1) coated with a 
lipid bilayer and ion channels (M2) (Krug & Fodor, 2013). Attached to the lipid bilayer of the 
virus are hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins at a ratio of four to 
one, respectively (Bouvier & Palese, 2008). HA being the most abundant surface glycoprotein is 
involved in the binding of the virus to the host’s sialic acid-containing receptors. NA, the other 
surface glycoprotein also interacts with sialic acid receptors by removing the sialic acid from the 
virus during virus budding from host cells (Krug & Fodor, 2013). These glycoproteins are where 
influenza virus strains derive their nomenclature from, an example is the H1N1 and H3N2 
strains, where the H stands for the subtype of hemagglutinin protein and the N is the subtype of 
neuraminidase protein (Bouvier & Palese, 2008).   
The largest RNA segments in the influenza A genome encode for the three polymerase 
proteins, segment 1 PB2, segment 2 PB1, and segment 3 PA (Krug & Fodor, 2013). However, 
segments 2 and 3 also encode for other proteins besides those involved in the polymerase 
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complex. Segment 2 encodes for two other proteins besides PB1, these are PB1-F2, which is a 
pro-apoptotic virulence factor, and PB1-N40, which is a truncated version of PB1 that is recently 
discovered. PA also encodes for a second protein through ribosomal frameshifting called PA-X, 
which has been shown to modulate virulence (Krug & Fodor, 2013). The next three segments in 
the influenza A genome only encode for a single protein, these are segment 4 HA, segment 5 
nucleocapsid protein (NP), and segment 6 NA (Krug & Fodor, 2013). Above we briefly 
described that HA and NA are surface glycoproteins involved in both the binding and budding of 
the virus, respectively. NP encapsulates the viral RNA located in the virus core and also plays a 
role in viral RNA replication. The last two segments 7, matrix protein (M), and 8, non-structural 
protein (NS), are spliced and the resultant mRNAs, spliced and un-spliced, are both translated 
(Krug & Fodor, 2013). The M segment encodes for M1 which as described above lies 
underneath the lipid membrane as part of the envelope, and M2 which encodes for the ion 
channels present in the lipid membrane and aid in the un-coating of the virus. For segment 8, the 
un-spliced mRNA encode for non-structural protein NS1 and the spliced mRNA encodes for two 
proteins involved in nuclear export, NS2 and NEP (Krug & Fodor, 2013).  
1.1.2 Hemagglutinin protein 
Influenza A HA is highly antigenic and these antigenic differences have led to the 
categorization of 18 HA subtypes named H1 – H18 ("Influenza Type A Viruses,"). HA subtypes 
H1 - 16 are capable of infecting avian species, whereas bats are the known host for H17 and H18 
virus strains ("Influenza Type A Viruses,"). HA is a membrane fusion protein located on the 
lipid membrane of the envelope that carries antigenic sites on the head domain. HA is initially 
found as the precursor HA0 which is cleaved into HA1 and HA2 (Skehel & Wiley, 2000). HA1 
is the head domain and is involved in binding to target cell receptors and is the location of the 
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antigenic sites and antibody binding (Lai & Freed, 2015; Skehel & Wiley, 2000). HA2 contains 
the fusion peptide, which catalyses membrane fusion and also has the transmembrane domain 
that anchors HA to the viral membrane (Lai & Freed, 2015).   
In the virus life cycle, HA has two roles the first being receptor binding to sialic acid 
receptors and the second being a membrane fusion protein (Gamblin & Skehel, 2010). Inside the 
host cell the virus replicates HA mRNA which is transcribed into HA0. HA0 is cleaved and 
becomes the two polypeptide chains HA1 and HA2. On the N-terminal of HA2 the fusion 
peptide is located and after refolding it forms the trimer interface, by which HA can now form a 
trimer (Gamblin & Skehel, 2010). Before the virus enters a host cell, HA recognizes the sialic 
acid receptors and binds to them initiating entrance to the host cell. There are two different sialic 
acid receptors: α(2,6) linkage which is recognized by influenza viruses of human origin and 
α(2,3) linkage which is recognized by viruses of avian origin (Skehel & Wiley, 2000). After 
receptor binding, HA mediates the fusion between the virus and the endosomal membrane in 
order to deliver the viral genome into the cell for replication. Release of the viral genome occurs 
by repositioning of the fusion peptide leading to a structural change in HA that creates a bridge 
between the virus and endosomal membrane (Gamblin & Skehel, 2010). 
1.1.3 Symptoms, pathogenesis, and transmission 
Influenza A virus can infect all age groups of people causing a wide range of respiratory 
infection from subclinical infections to the onset of lethal pneumonia (Nichelson, 1998). Persons 
at higher risk for hospitalization and possible complications due to infection include young 
children, the elderly, pregnant women, and those whom are immunocompromised (Hayden & de 
Jong, 2013). However, in uncomplicated influenza A infection, generally with the seasonal 
strain, symptoms usually include systemic symptoms such as fever, chills, and muscle pain, and 
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respiratory symptoms such as dry cough, a runny or plugged nose, and a sore throat. Persons 
usually present with a fever the day after infection followed by other systemic symptoms, which 
begin to dissipate three to four days presentation being replaced by the respiratory symptoms 
(Nichelson, 1998). After the systemic symptoms disappear persons will still feel lethargic and 
may take up to a couple weeks to resume higher intensity activities, such as exercising and sports 
(Hayden & de Jong, 2013). 
Influenza A infection can lead to complications or secondary infections in some people. 
The main complication with influenza infection is pneumonia, there are two types of pneumonia 
(McCullers, 2011). Primary influenza viral pneumonia is more commonly found in children and 
leads to respiratory failure, which can lead to mortality with rates of 25-50%. However, the 
implementation of an early antiviral treatment can decrease the mortality rate (Hayden & de 
Jong, 2013). Viral pneumonia was present in 50% of admitted patients infected with the 2009 
pandemic H1N1 virus or with the recently emerging avian H5N1 and H7N9 viruses. 
Epidemiologic analysis show that persons who develop viral pneumonia commonly have pre-
existing cardiac or pulmonary conditions, however, this is not the case for the 2009 pandemic 
virus and avian viruses (Hayden & de Jong, 2013). A second type of pneumonia experienced by 
influenza A-infected individuals is bacterial pneumonia. This occurs after people have acquired a 
secondary bacterial infection, most commonly caused by Streptococcus pneumoniae (Palacios et 
al., 2009). Bacterial pneumonia is the most common complication in influenza A infected 
persons. During the 1918 pandemic with Spanish influenza all most every fatal reported case was 
due to bacterial pneumonia, and in the following 1957 and 1968 pandemics 70% of life-
threatening pneumonia cases were caused by bacterial pneumonia. However, both viral and 
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bacterial pneumonia are more likely to occur in infected persons with underlying conditions 
(Hayden & de Jong, 2013). 
Transmission of influenza A in humans occurs through the release of respiratory 
secretions containing virus by coughing or sneezing. Infection in the upper and lower respiratory 
tract can occur from influenza A virus present in both large droplets and small aerosols from an 
infectious person traveling far distances to the new recipient (Ladhani et al., 2017). Human 
infection by avian, swine, and other species can occur through direct contact with the infected 
animal, including their waste. The initial site of infection for influenza A is the respiratory 
mucosa (Hayden & de Jong, 2013). Human influenza A viruses have preferential binding to the 
α2,6-linked sialic acid receptors, whereas avian strains preferentially bind α2,3-linked sialic acid 
receptors (Mair, Ludwig, Herrmann, & Sieben, 2014). In the human lung both the upper and 
lower respiratory tract are abundant in α2,6-linked sialic acid receptors compared to the α2,3-
linked sialic acid receptors, which are only found in the distal bronchioles. The distribution 
pattern of sialic acid receptors is one factor that could affect the pathogenicity of human versus 
avian influenza A strains (Mair et al., 2014). Avian viruses would therefore have more difficulty 
finding receptors to bind in a human host due to the depth of the lung the virus must reach to 
interact with the α2,3-linked sialic acid receptors. 
1.2 Influenza vaccines 
1.2.1 Vaccines currently available 
Every year for seasonal influenza the World Health Organization releases their 
recommendations on strains to be included in the vaccine for the upcoming fall in February of 
the same calendar year. Once the recommendation has been released the Influenza Working 
Group develops the vaccines to be distributed in Canada and submits them to the National 
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Advisory Committee on Immunization (NACI) for consideration. In Canada, only two categories 
of vaccines are authorized for use, they are inactivated and live attenuated vaccines ("Canadian 
immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2016-
2017," 2017).  
Inactivated vaccines used against influenza viruses in Canada are a mixture of split virus 
and subunit vaccines. Split virus vaccines contain virus that has been disrupted by a detergent. 
Subunit vaccines consist of the HA and NA proteins with the viral components removed 
("Canadian immunization guide chapter on influenza and statement on seasonal influenza 
vaccine for 2016-2017," 2017). Trivalent and quadravalent inactivated vaccines are authorized in 
Canada. In the trivalent vaccines there are two influenza A strains and one influenza B strain and 
in the quadravalent a second influenza B strain is added to the formulation ("Canadian 
immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2016-
2017," 2017). In adults over the age of 65, an inactivated vaccine containing 60 µg of HA protein 
in comparison to the 15 µg of HA protein administered to persons under 65 years of age. This 
elevated antigenic dose is administered to seniors because they sometimes need higher levels of 
antigen to invoke the desired immune response (Kumar et al., 2017). Children under two years of 
age are also considered a low responder group and they are administered an inactivated vaccine, 
which has the adjuvant MF59 is added. MF59 is a squalene oil in water emulsion, which is 
stabilized through the addition of surfactants (Mosca et al., 2008). MF59 is capable of decreasing 
the amount of influenza antigen needed for vaccination and provide enhanced and extended 
antibody titres (O'Hagan, 2007). 
The live-attenuated influenza vaccine is recommended for persons between the ages of 2 
and 59. It is an intranasal spray in which the influenza strains are attenuated and cold-adapted so 
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that they will only replicate in the nasal mucosa versus the lungs ("Canadian immunization guide 
chapter on influenza and statement on seasonal influenza vaccine for 2016-2017," 2017). 
FluMist® is quadravalent and has proven to have the highest efficacy compared to inactivated 
influenza vaccines in the designated age range mentioned above ("Canadian immunization guide 
chapter on influenza and statement on seasonal influenza vaccine for 2016-2017," 2017). Overall 
vaccination against influenza is highly recommended especially in the high-risk groups such as, 
persons with chronic health conditions, pregnant women, the elderly, infants, and aboriginal 
peoples.    
1.2.2 Experimental vaccines 
Since current vaccines are mainly developed with whole inactivated or live attenuated 
viruses, the antibody response is mainly biased towards the HA head region (Kim et al., 2017). 
The HA region is highly variable and therefore antibodies produced against one strain are not 
cross-reactive against the evolving virus. The overarching goal in influenza vaccine development 
is to create a universal vaccine that would provide broad spectrum protection across strains 
(Impagliazzo et al., 2015). These vaccines can include virus-like particle vaccines, chimeric HA 
vaccines, and HA stem targeting vaccines.  
Virus-like particle (VLP) vaccines are a more favourable alternative to the currently 
used live attenuated and split vaccines. The general description of VLP is that they mimic the 
virus structure and morphology without being infectious (Beljanski et al., 2015). The 
components of the vaccine include a strong glycoprotein immunogen, such as HA, and a potent 
adjuvant (Osterholm, Kelley, Sommer, & Belongia, 2012), and include NA and M proteins 
(Beljanski et al., 2015). Because they are non-infectious, they have excellent safety profile in 
comparison with currently available vaccines. Another advantage of VLP vaccines is that they 
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can be engineered to contain multiple antigens, allowing them to represent a broader population 
of strains (Beljanski et al., 2015). Overall these attributes make VLPs an attractive vaccine 
alternative to live-attenuated or split vaccines currently used. 
Chimeric vaccines are another experimental vaccine. Generally, the HA is the protein 
being mutated, an example is a chimeric H9 H5 vaccine where the head domain is derived from 
H9 and the stalk domain is derived from H5 (Kim et al., 2017). These vaccines account for the 
production of antibodies against both the head domain and stalk domain of HA. Although the 
stalk domain is less immunogenic due to its position on the virus, it is highly conserved 
throughout the different subtypes of HA (Kim et al., 2017). Experimental research showed that a 
chimeric vaccine was able to protect from lethal challenge against both avian H9N2 and H5N1 
viruses (Kim et al., 2017) because the host responded with production of antibodies against both 
the head and stalk domains of HA. Therefore, the main advantage of chimeric vaccines is that 
cross-protection is achieved against both virus subtypes utilized.  
Another experimental vaccine is one in which the highly-conserved HA stem is used as 
the vaccine antigen and it is the type of vaccine most people associate with a universal vaccine 
(Impagliazzo et al., 2015; Kim et al., 2017). Antibodies produced against the influenza A HA 
stem region are referred to as broadly neutralizing human monoclonal antibodies and were 
recently discovered, raising hope for a universal vaccine candidate (Corti et al., 2011; Ekiert et 
al., 2009; Ekiert et al., 2011). The construction of the HA stem alone has been challenging as the 
removal of the transmembrane domain and globular head domain lead to the loss of structural 
confirmation (Cohen, 2013). Therefore, even though large portions of HA are being deleted the 
stem antigen must maintain stability and structural resemblance to the full-length HA 
(Impagliazzo et al., 2015). There have been successful attempts at creating HA stem antigens 
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that induce the broadly neutralizing antibodies (Impagliazzo et al., 2015), however, there is still 
more experiments to be done to establish these as plausible universal vaccines. The major 
advantage of using the HA stem domain is the production of broadly neutralizing antibodies, 
however, the disadvantage is that the stem region is less immunogenic and therefore will need to 
be paired with a strong adjuvant.       
1.3 Adjuvants 
1.3.1 Purpose of adjuvants 
An adjuvant can be a natural or synthetic compound that is used to increase the immune 
response to a paired antigen (Alving, Peachman, Rao, & Reed, 2012; Awate, Wilson, Lai, 
Babiuk, & Mutwiri, 2012). Specifically, an ideal adjuvant will increase the quality, longevity, 
potency, and specificity of the immune response to the antigen (Alving et al., 2012). Vaccines 
are formulated to include adjuvants that are specifically tailored to promote the type of immune 
response most likely to clear the virus, bacteria or fungus (Alving et al., 2012). For example, 
retinoic-acid inducible gene I (RIG-I) ligands are involved in host defense against RNA viruses 
and therefore may be ideal adjuvants to include in antiviral vaccines (Patel & Garcia-Sastre, 
2014). Overall, an adjuvant should induce a robust immune response, including both humoral 
and cell mediated responses. The ratio of humoral versus cell mediated response depends on the 
type of pathogen, against the antigen and lead to antigen sparing and the elimination of a booster 
(Awate et al., 2012; Sivakumar, Safhi, Kannadasan, & Sukumaran, 2011). For example, if your 
vaccine is against tuberculosis you would want an adjuvant with an immune response skewed 
towards cell mediated, whereas for influenza you would want a response skewed towards a 
humoral response.   
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There are different types of adjuvants available to choose from depending on the immune 
response or delivery method desired for the paired antigen. Many of these adjuvants can be 
combined to increase the effectiveness of the desired response. For example liposomes generally 
contain cholesterol, for the purpose of binding and detoxifying saponins, a naturally derived 
product from tree bark, which are also an immune stimulated complex (ISCOM) (Sivakumar et 
al., 2011). The quenching of the toxic component by the cholesterol causes the toxic component 
to punch holes in the lipid layer instead of the cell membranes causing the release of the antigen 
(Alving et al., 2012). Adjuvants are also chosen for the immune response they elicit, which 
depending on the pathogen could be skewed to either Th1 or Th2 immune response. Mineral 
salts, which have been used for over a decade as adjuvants due to their potency (Sivakumar et al., 
2011), tend to have an immune response skewed towards Th2 (Mosca et al., 2008). As 
mentioned in the above paragraph the ability to reduce the amount of antigen used is a key 
feature of a good adjuvant. Oil-in-water emulsions have an antigen dose sparing effect by 
activating local immune cells leading to increased antigen presentation (Alving et al., 2012; 
Sivakumar et al., 2011). Some adjuvants due to their toxicity are only justifiable in certain 
situations for example cytokines, such as granulocyte-macrophage colony stimulating factor 
have been used to induce antigen presenting cells and primary immune response, making them 
useful in cancer vaccines, however, they are quite toxic which limits there use in other human 
vaccines (Sivakumar et al., 2011). Finally micro-particle adjuvants are usually biodegradable 
polymers which can be used to deliver the antigen to specific regions and be designed to allow 
for slow or gradual release of the antigen (Sivakumar et al., 2011). Micro-particles are therefore 
an example of an adjuvant which is used due to its ability to deliver antigens specifically and 
allow for depot effect. 
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1.3.2 Adjuvants currently available 
Since adjuvants are capable of increasing the immune response to paired antigens there 
have been many developed and approved for use in humans with specific vaccines. An example 
of a liposome adjuvant system used in a malaria vaccine is AS01S or AS01B. It is comprised of 
liposomes from detoxified monophosphorys lipid A and a detoxified saponin derivative (QS21) 
which are quenched by cholesterol. In this case the component to exert toxicity to make holes in 
the lipid layer is QS21 (Alving et al., 2012). AS02A is similar to the adjuvants mentioned above 
except squalene interacts with the cholesterol, which has shown to enhance stability and improve 
the overall effect of the adjuvant (Alving et al., 2012). Epaxal is a liposome based hepatitis A 
vaccine that induces both cellular and humoral immunity and lead to long term immunity 
(Sivakumar et al., 2011). Alum, which is a commonly used adjuvant due to its long history of 
use, can be derived from either aluminum hydroxide or aluminum phosphate. It has a short-term 
depot effect, induces a strong Th2 response, and can enhance uptake of the antigen by antigen 
presenting cells (Mosca et al., 2008; Sivakumar et al., 2011). The two main oil-in-water 
adjuvants available are MF59 and AS03, they contain 2% squalene and AS03 also contains 
vitamin E (Alving et al., 2012). MF59 and AS03 increase the uptake of antigen by antigen 
presenting cells and also have an antigen sparing effect (Alving et al., 2012). Even though many 
adjuvants are available for use in human vaccines, there is still much to be learned about them, 
including the mechanism of action for adjuvants such as alum. Therefore, current research looks 
to understand the mechanism of action and create safer and more immunogenic adjuvants to 
increase the efficacy of our vaccines. 
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1.3.3 Adjuvants used for influenza vaccines 
MF59 and AS03 oil-in-water emulsion adjuvants are the only adjuvants approved for 
use with influenza vaccines. MF59 adjuvant is included as part of the inactivated influenza virus 
vaccine administered to infants 0 -2 years old ("Canadian immunization guide chapter on 
influenza and statement on seasonal influenza vaccine for 2016-2017," 2017). AS03 has only 
been formulated with H5N1 vaccines stockpiled in case of a pandemic outbreak (Sun et al., 
2017). Since MF59 and AS03 are both oil-in-water emulsions they have a similar mechanism of 
action. Both of these adjuvants enhance the local immune response by increasing the uptake of 
the paired antigen as well as increase the presentation of the antigen on antigen presenting cells 
(Galson, Truck, Kelly, & van der Most, 2016).  
When looking at the influenza vaccines in development and the discussion of a 
universal vaccine, adjuvants are always part of the equation. Although the two currently used 
adjuvants are effective in increasing protective antibody titres against influenza antigens it is still 
important to strive for more effective adjuvants. Since influenza is an RNA virus it makes sense 
to develop adjuvants, which target the host’s defense systems against these viruses, which is the 
goal of this project. Recently toll-like receptor agonists have become a target for adjuvant 
development due to their role in host defence (Alving et al., 2012). Therefore, it makes sense to 
look at other host defense pathways, which are specific to the virus of interest. Influenza A virus 
is an RNA virus, which is sensed by retinoic acid-inducible gene I-like receptors in the 
cytoplasm therefore, the agonists for these receptors may be optimal adjuvants for RNA viruses. 
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1.4 Retinoic acid-inducible gene I (RIG-I)  
1.4.1 RIG-I structure 
Host recognition and defence against invading pathogens relies pattern recognition 
receptors (PRR) (Lassig & Hopfner, 2017; Patel & Garcia-Sastre, 2014; X. X. Xu et al., 2017). 
The activation of PRRs is important in both the innate immune response, which eliminates the 
pathogen at the site of infection, and the adaptive immune response, which induces long term 
immunity via antibodies (Patel & Garcia-Sastre, 2014). Retinoic acid-inducible gene I-like 
receptors (RLRs) are cytosolic viral RNA sensing receptors that are part of the vast superfamily 
2 (SF2), which are nucleic acid-dependent NTPases (Lassig & Hopfner, 2017). The RLR family 
consists of three different proteins which are; retinoic acid-inducible gene I (RIG-I), melanoma 
differentiation-associated gene 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2) 
(Lassig & Hopfner, 2017). 
RIG-I is a cytosolic receptor that recognizes blunt ended short double stranded RNAs 
(dsRNA) with a 5’ triphosphate moiety, leading to interferon (IFN)-β induction (Hornung et al., 
2006; Weber, 2015; X. X. Xu et al., 2017). There are three major domains in the RIG-I structure. 
They are the n-terminal tandem caspase recruitment domain (CARD), DExD/H-box helicase 
domain, and the c-terminal domain (CTD) attached by a flexible linker region (Kato et al., 2006; 
Weber, 2015). In the cell RIG-I can be found in two different states, activated or auto-inhibited 
(Figure 1). The auto-inhibited state occurs in uninfected cells, the CARD domain is bound tightly 
to the helicase domain and the CTD is free to scan the cytoplasm for ligands (Weber, 2015). 
Upon binding of the CTD to a ligand, RIG-I goes through a conformational change to an active 
or signaling state. In this state both the CTD and helicase domain bind the ligand, due to the 
helicase binding the ligand, the CARD domain is freed from inhibition (Weber, 2015). Once free 
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the CARD domain acts as a signal transducer leading to translocation to the outer mitochondrial 
membrane to interact with the adapter protein mitochondrial antiviral signaling (MAVS), which 
is also known as VISA, CARDIF or IPSI (Kawai et al., 2005; Meylan et al., 2005; Seth, Sun, Ea, 
& Chen, 2005; L. G. Xu et al., 2005).        
 
Figure 1: Schematic of RIG-I in both the auto-inhibited state and activated state after 
binding an agonist. 
 
1.4.2 RIG-I pathway 
In the host cell RNA containing a 5’ triphosphate moiety can be from two sources, the 
first being produced by host RNA polymerases and the second from viruses (Patel & Garcia-
Sastre, 2014). However, for 5’ triphosphate RNAs being produced by the host, the RNA 
polymerases either modify the 5’ end (RNA polymerases I and III) or cap the 5’ end (polymerase 
II) to no longer expose the 5’ triphosphate moiety. In comparison, viral RNA does not undergo 
any modifications leaving the exposed 5’ triphosphate end exposed for RIG-I to sense (Patel & 
Garcia-Sastre, 2014).  
When the CTD of RIG-I comes in contact with the blunt end 5’ triphosphate RNA the 
structure goes through a conformational change to the signaling state unmasking the previously 
bound CARD domain (Kolakofsky, Kowalinski, & Cusack, 2012). The released CARD domain 
is then ubiquitinated by Riplet (Oshiumi, Matsumoto, Hatakeyama, & Seya, 2009) and E3 ligase 
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TRIM25 (Gack et al., 2007) forming an active tetrameric unit. Once a RIG-I molecule bound to a 
ligand is ubiquitinated it forms a tetramer structure with two other ubiquitinated RIG-I molecules 
creating a lock-washer shaped structure (Peisley, Wu, Xu, Chen, & Hur, 2014), which once 
translocated to the outer mitochondrial wall is ready to interact with MAVS (Patel & Garcia-
Sastre, 2014).  
The interaction of the RIG-I tetramer with MAVS leads to the aggregation and 
redistribution of MAVS on the mitochondria leading to the formation of prion-like fibers, 
indicating activation (S. Liu et al., 2015; Patel & Garcia-Sastre, 2014). The E3 ligase family 
TRAF then ubiguitinates active MAVS leading to the activation of IKK and TBK1 kinases, 
which in turn phosphorylate MAVS (S. Liu et al., 2015). Once phosphorylated MAVS binds to 
interferon regulatory factor 3 (IRF3), due to this association IRF3 is brought in close contact 
with TBK1 and is subsequently phosphorylated. After phosphorylation IRF3 disassociates from 
MAVS and forms a dimer with another phosphorylated IRF3 through positively charged surfaces 
(S. Liu et al., 2015). The newly formed dimer can then relocate to the nucleus of the cell where it 
functions alongside nuclear factor (NF)-κB to turn on the expression of type-I interferons and 
other inflammatory cytokines (S. Liu et al., 2015).  
1.5 Hypotheses and objectives 
This project focuses on RNA-LZ-1, which is a small RNA molecule that has a strong 
binding affinity for the cytosolic receptor RIG-I. The main goals are to characterize cytokines, 
chemokines, and interferons induced by RNA-LZ-1 both in vitro and in vivo, as well as evaluate 
its potential as an adjuvant when formulated with an antigen against influenza A infection. We 
hypothesize that due to RNA-LZ-1’s binding affinity for RIG-I it will trigger a robust immune 
16	
	
response and a fortified adaptive response when used as an adjuvant. In order to address our 
hypothesis, we have separated our experiments into three clear objectives, which are as follows: 
1. To determine cytokines and interferons induced by RNA-LZ-1 in vitro, 
2. To determine cytokines, chemokines, and interferons induced by RNA-LZ-1 in vivo, and 
3. To determine the efficacy of RNA-LZ-1 as a potential adjuvant for influenza A virus in 
vivo. 
By addressing these objectives, we will test whether our hypothesis is correct or not. The 
following chapters discuss the experiments and results obtained for each of the objectives. 
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Chapter 2 RNA-LZ-1 induced immune response in vitro 
2.1 Introduction 
RNA-LZ-1 is a blunt ended, short double stranded RNA molecule with a 5' triphosphate 
moiety derived from the 3' and 5' non-coding regions of the influenza A genome (Figure 2). 
 
Figure 2: Schematic of RNA-LZ-1, derived from the 3’ and 5’ non-coding regions of the 
influenza A genome, which is a RIG-I agonist. 
 
Previously in our laboratory RNA-LZ-1 was shown to have a high binding affinity for 
RIG-I and to stimulate strong interferon response (Liu, Park, Pyo, Liu, & Zhou, 2015). In recent 
literature, it has been shown that RIG-I agonists have the potential to serve as adjuvants for 
vaccines against RNA viruses (Beljanski et al., 2015; Martinez-Gil et al., 2013). Since we know 
that in vitro RNA-LZ-1 binds to RIG-I and stimulates interferon promoter activity, we wanted to 
test this interaction further by showing the induction of type-I interferon (IFN) IFN-β, which is a 
hallmark of the RIG-I pathway. In vitro, we also wanted to show the induction of other 
inflammatory cytokines. To look into the production of these inflammatory cytokines and 
interferons we chose to use human cell lines from cell types that can be naturally infected by 
influenza including human lung epithelial cells and macrophages. The basic outline of this 
experiment is to transfect RNA-LZ-1 or polyI:C, a known RIG-I agonist, into the cell lines and 
by collecting the supernatant for protein expression and the cell lysate for RNA extraction, we 
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can quantify IFN-β levels at both the mRNA and protein level and other cytokines production at 
the protein level. These data will allow us to gain an overarching view of what is happening upon 
transfection of RNA-LZ-1. We hypothesize that RNA-LZ-1 will induce similar amounts of IFN-
β in comparison to polyI:C, since both are strong RIG-I agonists. 
2.2 Materials and methods 
2.2.1 Cell lines 
THP-1 human monocyte cells were maintained suspensory in RPMI-1640 media (ATCC, 
30-2001) containing 10% fetal bovine serum (Gibco, 16000-044), 100 times dilution of penicillin 
streptavidin (Gibco, 1514163), 55 µM beta-mercaptoethanol (Gibco, 21985-023), and 100 mM 
sodium pyruvate (Gibco, 11360-070). Cells were plated in 12-well plates at a density of 4 × 105 
cells/well and phorbol myristate acetate (PMA) (Sigma-Aldrich, P8139-1mg) was added to 
differentiate the monocytes into macrophages. A549 human lung epithelial cells were maintained 
in F-12K media (Gibco, 21127-022) containing 10% fetal bovine serum and 100 times dilution 
of penicillin streptavidin (Gibco, 15140163). A549 cells were plated in a 12-well plate at a 
density of 2.5 ×	105 cells/well.  
2.2.2 RNA-LZ-1 synthesis 
T7 in vitro transcription, MEGAshortscript kit (Ambion Life Technologies, AM1354), 
was used to synthesize the RNA-LZ-1. Fifty nanograms of both the T7 promotor primer and the 
RNA-LZ-1 primer, sequence 5’mGmGCAAAAGCAGGGTACGAATACCCTTGCTTTTG 
CCTATAGTGAGTCGTATTAAATT-3’, were annealed together by heating the mixture up to 
95ºC for five minutes and then slowly cooling the mixture to 4ºC. By annealing the primers a 
template sequence is made, the template is then diluted ten times in RNase free water so that a 
concentration of 5 pmol/µl is achieved. One microliter was then incubated with T7 enzyme mix, 
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rNTPs (150 nmol/each), 10 × T7 buffer, and RNase free H2O overnight at 37ºC. Turbo DNase 
was then added to the mixture and incubated at 37ºC for 15 minutes. The turbo DNase is added 
to degrade any remnants of template DNA in the mixture. RNA-LZ-1 was then purified using a 
mini quick spin column (Sigma, 11814427001). First the column matric needs to be re-
suspended by gentle flicking. Next centrifuge the column at 1000 g for 1 minute to remove any 
residual buffer. The RNA-LZ-1 mixture can then be added to the column and centrifuged for 4 
minutes at 1000 g. RNA-LZ-1 was then present in the eluant and a nanodrop2000 (Thermo 
Scientific) was used to determine the concentration.   
2.2.3 Transfection 
A549 cells and differentiated THP-1 cells were transfected with 1 µg of either RNA-
LZ-1 or low molecular weight (LMW) polyI:C (Invivogen, tlrl-picw). The day after cells were 
seeded, wells were checked for confluency (60-80%) before being transfected. Opti-MEM 
(Gibco, 31985-070) was added to two 1.5 ml tubes, 150 µl per tube. In one tube 15 µl of 
Lipofectamine RNAiMAX (Invitrogen, 13778-150) was added, in the other tube 1 µg of either 
RNA-LZ-1 or LMW polyI:C was added. The diluted RNA was then added to the diluted 
Lipofectamine RNAiMAX tube, a 1:1 dilution ratio, and let incubate at room temperature for 30 
minutes. After the incubation period the transfection mixture is added drop wise to the 
designated well. The cells are then incubated with the transfection mixture for ~16 hours at 37°C 
before media is replaced. Cells are then incubated for another 32 hours, 48 hour total incubation, 
before supernatant is collected and stored at -80°C and RNA is extracted from the cells.  
2.2.4 RNA isolation and real-time quantitative polymerase chain reaction (qPCR) 
RNA was extracted from transfected cells using the TRIzol extraction method. After the 
supernatant was removed from the well 1 ml of TRIzol reagent (Ambion, 15596018) was added 
20	
	
to the cells. The TRIzol was gently pipetted up and down to remove the cells from the bottom of 
the well and lyse them. After moving the homogenized TRIzol and cell mixture to a 1.5 ml tube 
the mixture was incubated for 5 minutes at room temperature. Chloroform (Sigma, C2432-
500ml) was then added to the TRIzol mixture and the tube was shaken vigorously for 15 seconds 
and incubated at room temperature for 3 minutes. The sample was then centrifuged for 12,000 g 
for 15 minutes at 4°C. The aqueous phase, which contains the RNA, was then moved into a new 
tube and isopropanol (Sigma, 19516-500ml) was added to isolate the RNA. Incubation was 10 
minutes at room temperature before centrifuging 12,000 g for 10 minutes at 4°C. The RNA could 
now be seen visually as a white pellet at the bottom of the tube. To wash the RNA 75% ethanol 
made in diethylpyrocarbonate (DEPC) containing H2O (Invitrogen, 46-2224) was used. The 
sample is vortexed briefly and centrifuged at 7,500 g for 5 minutes at 4°C. The RNA pellet was 
then air dried for 10 minutes before being re-suspended in RNase free H2O. Finally, the re-
suspended RNA was incubated at 55°C for 15 minutes before determining the concentration 
using a nanodrop2000 (Thermo Scientific) and being stored at -80°C. 
Reverse transcription was done using 500 ng of RNA to make cDNA for qPCR. First 
the RNA was treated with 100U DNase I (Invitrogen, 18068-015) to degrade any genomic DNA 
that may still be present in the RNA sample before we convert it back into DNA. The DNase I 
mixture was incubated at room temperature for 15 minutes and then 25 mM EDTA (Invitrogen, 
Y02353) was added, aiding in inactivation of DNase I, and the mixture was incubated again at 
65°C for 10 minutes. A 10 mM dNTP mix (Invitrogen, 18427-088) and 50 µM of oligo(dT) 
primer were added to the sample and incubated at 65°C for 5 minutes then moved onto ice for 
another 2 minutes. The final reverse transcription reaction was then done, 5 × FS buffer 
(Invitrogen, Y02321), 0.1 M DTT (Invitrogen, Y00147), RNase out (Invitrogen, 10777-019), and 
21	
	
superscript III reverse transcriptase enzyme (Invitrogen, 18080-044) were are all added to the 
mixture and incubated at 50°C for 1 hour and then heated to 70°C for 15 minutes. The cDNA 
diluted 10 times in DEPC H2O was then ready to use for qPCR to detect IFN-β mRNA levels. 
IFN-β was the gene of interest and GAPDH was used as a housekeeping gene. SYBR green 
master mix (Applied Biosystems, 4367659) and 10 µM of each primer were added to the 
designated tubes for qPCR and ran on a real time PCR system (StepOnePlus, Applied 
Biosystems). Results were quantified using the ΔΔCT method (Lin et al., 2012). 
2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
The supernatant from the transfected samples was used to detect IFN-β protein levels. A 
96-well plate was coated with 0.2 µg/µl of purified anti-human IFN-β (R&D, AF814) in coating 
buffer (0.015 M NaCO3, 0.035 M NaHCO3 in ddH2O, pH 9.6) and left at 4°C overnight. The 
next day the plate was washed four times in 1 × TBST (0.1 M Tris, 0.17 M NaCl, 0.05% Tween 
20 in ddH2O) before being blocked with 1% bovine serum albumen (BSA) (Sigma-Aldrich, 
A7906-100g) for 1 hour. After the blocking time was completed the plate was washed four times 
again with 1 × TBST. The standard was then added to the plate, starting at a concentration of 
4000 pg of human IFN-β (Temecula California, 92590), and was serially diluted 2-fold down the 
plate wells A-G with well H being the blank. Supernatant samples were then added in triplicate 
and the plate was incubated at room temperature for 2 hours. The plate was then washed again 
before the secondary antibody, biotin labelled rabbit anti-human IFN-β (Abcam, ab84258), was 
added at a concentration of 1 µg/µl in 1 × TBST containing 0.1% BSA. The secondary antibody 
was incubated for 1 hour at room temperature. A 1 in 5000 dilution of streptavidin (Jackson 
Immuno Research Laboratory Inc., 016-050-084) in 1 × TBST containing 0.1% BSA was added 
to the plate after washing and was incubated at room temperature for another hour. After the 
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final wash a 1 in 100 dilution of p-nitrophenyl phosphate substrate (PNPP) (Sigma, N3254) in 
PNPP buffer (1% diethanolamine, 0.5 mM MgCl2 in ddH2O) was added and colour development 
was observed before reading the plate. 
2.2.6 Human multiplex analysis 
A human multiplex assay kit (Invitrogen, LHC0001M) was used to assess multiple 
immune related cytokine protein levels in the supernatant from transfected THP-1 and A549 
cells. Magnetic beads coupled to antibodies of choice cytokines were added to a 96-well plate. 
Supernatant diluted 1 to 1 in assay diluent was added to the beads in duplicate and incubated for 
two hours at room temperature. The plate is then washed 3 times before a 10 times dilution of 
biotinylated detector antibody was added. The detector antibody binds to any available proteins 
of interest. After a final wash 10 times diluted streptavidin-RPE fluorescent tag in RPE-diluent 
was added to the beads and incubated for 30 minutes at room temperature in the dark shaking on 
an orbital shaker. Once the incubation period was over a Bio-Plex 200 system powered by 
luminex xMAP technology (BioRad) was used to read protein levels.   
2.2.7 Statistical analysis 
A one-way ANOVA with Tukey’s multiple comparisons test was used to statistically 
analyze all data from this objective using GraphPad Prism software. 
2.3 Results 
2.3.1 RNA-LZ-1-specific production of interferon (IFN)-β 
Induction of IFN-β was measured at both the protein level and mRNA level in vitro. 
RNA-LZ-1 was transfected into both human lung epithelial cells and human macrophages and 
ELISA and qPCR were used to determine protein levels and mRNA levels, respectively. A549 
epithelial cells and THP-1 macrophage cells incubated with RNA-LZ-1 resulted in a significantly 
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induced amount of IFN-β protein in comparison to the mock, transfection reagent control, and 
polyI:C groups (Figure 3; p<0.0001; p<0.0001; p˂0.0001). In THP-1 human macrophages both 
RNA-LZ-1 and polyI:C significantly induced IFN-β mRNA fold change in comparison to the 
mock and transfection reagent control groups (p˂0.0001) (Figure 4). However, in A549 epithelial 
cells only polyI:C and not RNA-LZ-1 was able to significantly increase mRNA fold change 
(Figure	4;	p=0.001).	 
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Figure 3: IFN-β protein expression in human epithelial cells and macrophages post-
transfection with the RNA-LZ-1. Cells were transfected with 1 µg of either polyI:C, RNA-LZ-
1 or an equivalent volume of media with or without the transfection reagent. At 20 hours post-
transfection supernatant was collected and used for IFN-β protein analysis with ELISA. 
Statistical analysis was done using a one-way ANOVA where the p-value was <0.0001. 
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Figure 4: IFN-β mRNA fold change expression was measured in human epithelial cells and 
macrophages post-transfection with RNA-LZ-1. Cells were transfected with 1 µg of either 
polyI:C or the RNA-LZ-1 or an equivalent volume with or without transfection reagent. At 20 
hours post-transfection cells were collected and RNA was extracted. cDNA was synthesized 
from 500ng of RNA and used for quantitative real-time PCR. Statistical analysis was done using 
a one-way ANOVA (** p= 0.001, **** p<0.0001). 
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These results match what we were expecting since RNA-LZ-1 has a known affinity for 
RIG-I binding (G. Liu et al., 2015). At both the protein and mRNA level RNA-LZ-1 was able to 
induce high amounts of IFN-β compared to the mock and transfection control. Since we 
confirmed RNA-LZ-1’s ability to significantly induce IFN-β production we can move forwards 
to characterize inflammatory cytokines being produced by RNA-LZ-1 in vitro. 
2.3.2 RNA-LZ-1-specific production of inflammatory cytokines and chemokines 
Once confirming that RNA-LZ-1 does indeed induce the RIG-I pathway, we wanted to 
look at other cytokines involved in the inflammatory response pathway. A multiplex assay was 
used to measure the protein levels of multiple cytokines in the supernatant. This method was 
chosen because in one well you are able to measure the expression of multiple proteins. 
Significant induction of interleukin (IL)-6 by RNA-LZ-1 in comparison to the mock control was 
observed in THP-1 (Figure 5A; p˂0.0001) and in comparison to all the other groups in A549 
cells (Figure 5B; p=0.0005). IL-8 induction by RNA-LZ-1 was were observed in both cell types 
as well (Figure 5). In THP-1 cells the transfection reagent control, polyI:C, and RNA-LZ-1 
induced IL-8 in comparison to mock (Figure 5A; p˂0.0001). Whereas in A549 RNA-LZ-1 
induced significant levels of IL-8 in comparison to all the other treatment groups (Figure 5B; 
p˂0.0001). High levels of IL-8 were observed in all groups in the THP-1 cells (Figure 5A), this 
has been shown to be due to IL-8 containing archetypal AU-rich elements in its 3’-untranslated 
regions, which keep the mRNA abundant and stable in human macrophages (Mahmoud et al., 
2014). In THP-1 macrophages a slight induction of IL-1β was observed by RNA-LZ-1 compared 
to the mock group (Figure 5A; p=0.05). Neither polyI:C or the transfection control induced IL-1β 
levels compared to the mock group. IL-4 and TNF-α induction was observed in human 
macrophages by RNA-LZ-1, however, it was not significant compared to the mock group 
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(Figure 5A). In the lung epithelial cells there were no other cytokines induced by any of the 
treatment groups besides IL-6 and IL-8, described above (Figure 5B).  
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Figure 5: Cytokine protein levels induced by the RNA-LZ-1 in vitro. THP-1 cells (A) and 
A549 cells (B) were transfected with 1 µg of either polyI:C or RNA-LZ-1 or infected with a PR8 
NS1 deletion virus at an MOI of 5. Cells were then incubated for 24 hours and supernatant was 
collected. Supernatant was used for protein analysis by the multiplex assay. Statistical analysis 
was done using a one-way ANOVA for each cytokine (* p=0.05, *** p=0.0005, **** 
p=<0.0001). 
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The differing results in the THP-1 macrophage cell line compared to the A549 epithelial 
cells was expected, as upon activation of the inflammatory pathway and the expression of 
interferon regulatory factor-3 (IRF-3) (Thomas, Galligan, Newman, Fish, & Vogel, 2006), 
downstream of RIG-I activation, a cascade of inflammatory genes are expressed in macrophage 
cells. These data indicate that RNA-LZ-1 is capable of inducing a downstream inflammatory 
response due to MAVS signalling through IRF-3. These results strengthen the results of our first 
objective by showing that RNA-LZ-1 is capable of inducing a broad spectrum of inflammatory 
cytokines in vitro. 
2.4 Discussion 
RNA-LZ-1 was capable of inducing a wide variety of inflammatory cytokines and 
interferons in vitro. These results strengthened previous data stating that RNA-LZ-1 is a strong 
RIG-I ligand (G. Liu et al., 2015). In comparison to polyI:C, which is a known RIG-I ligand 
(Kato et al., 2008), RNA-LZ-1 was able to produce higher protein levels of IFN-β and 
inflammatory cytokines in vivo in comparison to the mock control group. PolyI:C is not only a 
RIG-I agonist it is also an agonist of toll-like receptor 3 (Lee et al., 2016). In THP-1 human 
macrophages toll-like receptor 3 is not present (Carpenter, Wochal, Dunne, & O'Neill, 2011), 
therefore, polyI:C is only activating one of its compatible pathways, which could account for the 
non-significant increase in levels of inflammatory proteins observed in the polyI:C group (Figure 
5A). All cytokines produced were pro-inflammatory and indicative of a Th1 immune response 
(Lyke et al., 2004). As mentioned above an explanation for why the induction of these cytokines 
was more prevalent in the THP-1 cells is because macrophages are the dominant cell type 
producing these cytokines downstream of IRF3 signaling (Thomas et al., 2006). The results from 
this objective give us solid evidence that RNA-LZ-1 could act as an adjuvant, due to the robust 
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immune response seen in vitro. Since we have observed this inflammatory response in vitro the 
next logical step is to look at the effects of RNA-LZ-1 in vivo.  
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Chapter 3 Transitioning RNA-LZ-1 from an in vitro model to an in 
vivo model 
3.1 Rational 
RNA-LZ-1 was capable of inducing significant amounts of IFN-β in both human 
macrophages and lung epithelial cells. An increase in inflammatory cytokine protein levels was 
also observed in both cell types. This observation of inflammatory cytokines and interferon 
induction in vitro was also observed in another study working with a RIG-I agonist derived from 
vesicular stomatitis virus, M8 (Chiang et al., 2015). M8 was also proven to provide protection 
against a paired influenza A antigen in a mouse model (Chiang et al., 2015). Therefore, since 
RNA-LZ-1 and M8 should be activating the same pathway we want to characterize an in vivo 
model, which will test RNA-LZ-1 as a potential adjuvant. To properly develop an in vivo mouse 
model, we need to first determine the optimal dose and characterize the immune response gene 
profile. Chapter 4 will address the development of a mouse model for RNA-LZ-1 injection. 
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Chapter 4 RNA-LZ-1 induced immune response in vivo 
4.1 Introduction 
In order to characterize how RNA-LZ-1 induces an inflammatory response as an 
adjuvant, it is important to understand the immune response being elicited by RNA-LZ-1 alone. 
In vitro we have shown that RNA-LZ-1 binds to the cytosolic sensor RIG-I (G. Liu et al., 2015) 
and activates the downstream inflammatory response, including induction of IFN-β and the NF-
κB pathway, therefore, we know at least part of the mechanism of inflammatory induction by 
RNA-LZ-1. Knowing the mechanism by which a potential adjuvant acts is essential knowledge 
that adds to the safety profile of RNA-LZ-1 and justifies moving forwards with testing in vivo. 
Moving into a mouse animal model we first wanted to determine the optimal dose of RNA-LZ-1 
which we expect will be different than that used in the cell culture studies. The doses used were 
chosen based on previous literature working with small RNA molecules, which were RIG-I 
ligands (Goulet et al., 2013). The dosage trial revealed that the optimal dose was 5 µg of RNA-
LZ-1 based on the broad induction of inflammatory cytokines, chemokines, and interferons 
(Figure 6). After the correct dose was determined we wanted to know at what time points 
inflammatory cytokines, chemokine, and interferons are upregulated which in turn would 
establish the length of time which RNA-LZ-1 induces a local immune response. In this objective, 
we also looked at the kinetics of a previously tested adjuvant, VIDO’s triple adjuvant, this was to 
compare the immune responses between a proven adjuvant and RNA-LZ-1. We hypothesize for 
this objective that RNA-LZ-1 will produce a robust immune response in vivo. 
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4.2 Materials and methods 
4.2.1 Formulation of RNA-LZ-1 injection 
RNA-LZ-1 was paired with the in vivo transfection reagent in vivo-jetPEI (Polyplus 
transfection, 201-106) for all injections. The transfection reagents mediates an efficient delivery 
of DNA, RNA, etc. to a wide range of animal tissues. Based on previous literature (Beljanski et 
al., 2015) the amounts of 1, 2.5, and 5 µg of RNA-LZ-1 were chosen to be used in the dosage 
trial. When complexing RNA-LZ-1 with in vivo-jetPEI the first thing to consider is the N/P ratio, 
which is defined as the ionic balance within the complex and is the number of nitrogen residues 
in in vivo-jetPEI per nucleic acid phosphate. The manufacturer suggests an N/P value between 6 
and 8, so we used an N/P ratio of 8 for all studies. The amount of in vivo-jetPEI can be calculated 
using a simple equation provided in the protocol booklet: 
𝜇𝑙	𝑜𝑓	𝑖𝑛	𝑣𝑖𝑣𝑜 − 𝑗𝑒𝑡𝑃𝐸𝐼 = 𝜇𝑔	𝑅𝑁𝐴×3 𝑁𝑃 𝑟𝑎𝑡𝑖𝑜150  
Equation 1: Equation to determine the amount of in vivo-jetPEI needed for a specified 
amount of RNA. The N/P ratio used was 8. This equation is from the in vivo-jetPEI protocol 
booklet provided with the reagent from Polyplus transfection. 
 
The specified RNA-LZ-1 concentration was added into half the injection volume of 
double distilled H2O and 5% glucose, provided in the kit. The calculated amount of in vivo-
jetPEI was added to the other half of the injection volume. Each tube is briefly vortexed and then 
the diluted in vivo-jetPEI is added to the RNA-LZ-1 tube and vortexed gently before being 
incubated at room temperature for 15 minutes. The injection is now complexed and is stable at 
4°C for up to 7 days according to the manufacturer (Polyplus transfection).   
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4.2.2 Ethics statement 
In vivo studies were performed at the Vaccine and Infectious Disease Organization – 
International Vaccine Center (VIDO-InterVac), University of Saskatchewan. All procedures and 
animal care complied with the ethical guidelines of the Canadian Council of Animal Care and 
the University of Saskatchewan Committee on Animal Care and Supply. The following 
experiments were approved by the University of Saskatchewan Animal Ethics Board. 
4.2.3 Dosage mouse trial 
Naïve female BALB/c mice (Charles River) at six weeks of age were used in this study. 
Animals were randomly assigned into six groups (N=5). RNA-LZ-1 was injected at three 
different doses (1, 2.5, and 5 µg) alongside in vivo-jetPEI transfection reagent (described above). 
Each dose of RNA-LZ-1 had its own control group consisting of the specified volume of in vivo-
jetPEI in double distilled H2O with 5% glucose. Mice were allowed to acclimatize for 1 week 
before receiving their specific injection, which was given intra-muscularly into the semi-
membranous muscle with 25 µl of injection per leg. The intra-muscular injection route was 
chosen for all animal trials as influenza vaccines are given intra-muscularly in humans. After 24 
hours mice were sacrificed and the injection site, semi-membranous muscle, was removed.  
4.2.4 Dual Luciferase assay 
Human embryonic kidney cells (HEK293T) were plated in a 24-well plate at a density 
of 2 ×	105 cells per well the night before the assay. The next day cells were transfected with 
plasmids expressing RIG-I, IFN-β promoter firefly luciferase, and renilla luciferase using 
TransIT-LTI transfection reagent (Mirus, MIR2300). Six hours post-transfection the cells were 
transfected with the RNA-LZ-1 or polyI:C, using RNAiMAX transfection reagent. Twenty-four 
hours post-transfection cells were lysed using passive lysis buffer. A one to one ration of LarII 
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(Promega, E1960) to sample was mixed together and the firefly luciferase concentration was 
read. Next the same volume of Stop and Glo (Promega, E1960) was added to quench the firefly 
luciferase and activate the renilla luciferase. Then the ratio between the two luminescence was 
determined. 
4.2.5 Formulation of VIDO’s triple adjuvant and the modified triple adjuvant 
VIDO’s triple adjuvant was formulated as described below. The polyI:C (Invivogen, 
tlrl-picw), host defence peptide (peptide) (CPC Scientific Inc., 818360), and polyphosphazene 
EP3 (VIDO EP3 Lot A) were added at a 1:2:1 ratio respectively. PolyI:C (10 µg/mouse) and 
peptide (20 µg/mouse) were complexed together by incubating the mixture for 15 minutes with 
PBS pH 7.4 (Gibco, 10010-031) at room temperature. The light sensitive polyphosphazene EP3 
(10 µg/mouse) was then added and the mixture and incubated for another 15 minutes at room 
temperature. The adjuvant mixture was then stored in the dark at 4°C until needed for injection. 
In the case of the modified triple adjuvant the same procedure is followed except 10 µg per 
mouse of RNA-LZ-1 replaced polyI:C in the formulation. 
4.2.6 Kinetics mouse trial  
Naïve, 6-week old female BALB/c mice were split into treatment and control groups 
(N=5) for each of the following time points 3, 6, 24, 48, and 72 hours post-injection. On day 0 
mice were injected intra-muscularly into the semi-membranous muscle, 25 µl per leg, with either 
5 µg of RNA-LZ-1 complexed with in vivo-jetPEI, in vivo-jetPEI control, VIDO triple adjuvant, 
modified triple adjuvant, or PBS. At the designated time points each group of mice were 
sacrificed and the injection site tissue was collected.  
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4.2.7 RNA isolation from injection site 
RNA was extracted from the injection site tissue using the TRIzol extraction method. 
The semi-membranous muscle had any excess fat trimmed from it and was then cut into smaller 
pieces before being placed in a bead beater tube. One milliliter of TRIzol reagent was added to 
the tube then the tissue was homogenized in a bead beater (Biospec Products) for approximately 
16 seconds at speed setting 48. After homogenization samples were incubated for 5 minutes at 
room temperature, allowing the dissociation of nucleoprotein complex. Chloroform was then 
added to the sample and shaken vigorously for 15 seconds before being incubated for 2 minutes 
at room temperature. Samples were then centrifuged at 12,000 g for 15 minutes at 4°C. The 
RNA, which is located in the aqueous phase, was moved to a new tube where isopropanol was 
added to precipitate the RNA. The isopropanol and aqueous phase mixture was incubated for 10 
minutes at room temperature and then centrifuged at 12,000 g for 10 minutes at 4°C. A white 
pellet, the RNA, should be visible after centrifugation. The RNA pellet was then washed with 
75% ethanol by vortexing the sample briefly before centrifuging 7,500 g for 5 minutes at 4°C. 
Discarding the wash the pellet was allowed to air dry for 10 minutes before being re-suspended 
with RNase-free water. Once re-suspended the RNA was heated to 55°C for 15 minutes. The 
concentrations of the samples were then determined using a nanodrop2000 (Thermo Scientific) 
and stored at -80°C.  
4.2.8 Real-time quantitative PCR 
cDNA, derived from 500ng of extracted RNA from the animal trials, was used as 
template for qPCR. Samples were run in triplicate against twenty different cytokines, 
chemokines, and interferons to test for mRNA expression levels. Three different housekeeping 
genes, GAPDH, β-actin, and HPRT, were run as internal controls. The most consistent 
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housekeeping gene for all samples was used as the control. Primers used in both trial are 
available in the appendix.  
4.2.9 Statistical analysis 
Statistical analysis was performed using a one way or two way ANOVA in GraphPad 
Prism software. 
4.3 Results 
4.3.1 Optimal dosage of the RNA-LZ-1 in vivo 
For our dosage trial, we selected RNA-LZ-1 concentrations, 1 µg, 2.5 µg, and 3 µg based 
on a literature search on RIG-I agonists being tested in vivo. Animals were injected intra-
muscularly into the semi-membranous muscle and sacrificed 24 hours post-injection. The 
injection site tissue and serum (data not shown) were then analyzed for cytokine, chemokine, and 
interferon response. In the serum, there was no detection of any cytokine proteins of interest 
(data not shown). However, we were able to observe gene activation of inflammatory cytokines 
and interferons for RNA-LZ-1.  
Overall there was an increase in gene activation of cytokines and chemokines in four 
different functional areas. The first area comprised of an increase in interferon activity (Figure 6 
B and C). Only the 5 µg concentration of RNA-LZ-1 was able to induce significant fold change 
in comparison to the control group, the other concentrations tested were comparable to that of the 
control group (Figure 6 B and C) (p˂0.0001; p˂0.0001). The induction of interferons are 
important to observe as they are the hallmark of activation by the RIG-I pathway. Secondly 
activation of genes responsible for T-cell and B-cell maturation and differentiation was observed 
(Figure 6 D and E). IL-12β for instance plays an important role in sustaining sufficient numbers 
of effector and memory Th1 cells, which are essential for mediating long term memory (Stobie et 
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al., 2000). For IL-12α and β only the 5 µg concentration induced a significant up-regulation of 
mRNA, like the interferons the other two concentrations were similar to background levels 
observed in the mock groups (Figure 6 D and E) (p˂0.0001; p˂0.0001). However, for CCL3 
(Figure 6H) there was a significant induction of fold change for both the 1 µg and 5 µg 
concentrations (p=0.001; p=0.0005), with only the 2.5 µg concentration reflecting background 
levels. We would have expected to see a dose dependency for CCL3 (Figure 6H) since there was 
induction at the high and low concentrations, however, that was not the case. The third area with 
increased activity surrounded chemokines involved in inflammatory cell response, including the 
recruitment of neutrophils and eosinophils (Figure 6 G, H, and I). CCL2 (Figure 6G; p˂0.0001) 
and CCL5 (Figure 6I; p˂0.0001) saw increased fold change at the 5 µg concentration but not at 
the 1 or 2.5 µg concentrations. This is crucial to observe as inflammatory cell recruitment is 
needed to mount an effective immune response against incoming pathogens. Inflammatory 
cytokine induction was the last area in which gene activation was observed (Figure 6F; 
p˂0.0001), IL-6 induction was only observed for the 5 µg dose. For this trial we also looked at 
gene activation of the anti-inflammatory cytokine IL-10 as a negative control (Figure 6A), like 
expected there was no upregulation of this gene by any of the RNA-LZ-1 concentrations. After 
comparing the upregulation of genes involved in the inflammatory response the RNA-LZ-1 
concentration of 5 µg had the broadest effect in vivo. Moving forwards the 5 µg concentration 
will be used to explore the kinetics of RNA-LZ-1.  
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Figure 6: Cytokine and chemokine induction due to RNA-LZ-1. Six-week-old female 
BALB/c mice were intramuscularly injected with three different doses (1 µg, 2.5 µg, and 5 µg) 
of RNA-LZ-1. Twenty-four hours post-injection mice were euthanized and the semi-
membranous muscle from both hind legs were collected. Total RNA was extracted from the 
semi-membranous muscle using the TRIzol method. 500 ng of total RNA was used for reverse 
transcription into cDNA by the oligo(dT) primer. Cytokine and chemokine expression levels 
were detected using real-time PCR with gene-specific primers. The mRNA fold change was 
determined using the ΔΔCT method and normalized against the CT values of the housekeeping 
gene GAPDH. Statistical analysis was done using a two-way ANOVA for each cytokine (* 
p=0.05, ** p0.001, *** p=0.0005, **** p<0.0001). 
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4.3.2 Kinetics of immune response genes induced by the RNA-LZ-1 
Now that we have determined the optimal dose of RNA-LZ-1 in vivo, 5 µg, we decided to 
look at the immune response elicited at other time points. The first-time point trial we did looked 
at the effects of RNA-LZ-1 at 24, 48 and 72 hours post-injection. Cytokine and chemokine 
analysis was done using quantitative real-time PCR. Unlike what we were expecting to observe, 
RNA-LZ-1 did not appear to activate any of the genes examined at both 48 and 72 hours post-
infection. There was no upregulation of IFN-β, IFN-ɣ, or IL-1β genes (data not shown) and no 
significant gene activation of either IL-12α (Figure 7A) or IL-6 (Figure 7B), which were highly 
up-regulated in the previous dosage trial at 24 hours post-injection (Figure 7). 
The results of the second mouse trial were unexpected compared to the initial dosage 
trial, leading us to question whether RNA-LZ-1 was still biologically functional or if the effects 
of RNA-LZ-1 dissipate by these later time points. To test whether RNA-LZ-1 was still functional 
an IFN-β dual luciferase assay was done. RNA-LZ-1 was transfected into HEK293T cells at both 
200 ng and 500 ng concentrations and polyI:C transfected at the same concentrations was used as 
a positive control. RIG-I was transfected in order to see the IFN response, as HEK293T cells 
have low levels of endogenous RIG-I. In addition green fluorescent protein (GFP) was 
transfected as a control for the transfection of RIG-I in order to show that RNA-LZ-1 is RIG-I 
dependent (Figure 8). RNA-LZ-1 and polyI:C increased in a dose dependent manor compared to 
the control group (Figure 8). The dual luciferase assay showed us that RNA-LZ-1 was still 
biologically functional and that even after long term storage at -80°C the integrity of RNA-LZ-1 
is not compromised. Based on the fact that RNA-LZ-1 maintained its biological functionality the 
results observed in Figure 6 can be attributed to the dissipation of the immune response induced 
by RNA-LZ-1 at these later time points. 
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Figure 7: Comparison of the RNA-LZ-1 gene activation at 24, 48, and 72 hours post-
injection. Six-week-old female BALB/c mice were injected with either RNA-LZ-1 or the control 
intra-muscularly into the semi-membranous muscle. Injection site tissue was harvested at 
designated time points. RNA was extracted from the tissue and 500 ng was used to generate 
cDNA for real-time qPCR. The mRNA fold change was determined using the ΔΔCT method and 
normalized against the CT values of the housekeeping gene GAPDH.   
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Figure 8: IFN-β induction due to RNA-LZ-1 is dependent upon the presence of RIG-I. 
RNA-LZ-1 and polyI:C were transfected at a concentration of either 200ng or 500ng with or 
without RIG-I in A549 cells. IFN-β production was measured using the INF-β dual luciferase 
assay, where renilla luciferase acts as an internal control. This showed that the production of 
IFN-β by RNA-LZ-1 and polyI:C is both RIG-I and dose dependent. 
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The next time points we chose to look at were 3, 6, and 24 hours post-injection. This 
data provided two patterns of gene up-regulation (Figure 9). The first being highly up-regulated 
at the earliest time point and slowly dissipating towards 24 hours (Figure 9B) and the second 
being a peak at the middle time point and low up-regulation at the early and late time points 
(Figure 9A, C-L). This trial resulted in a wider up-regulation of inflammatory genes than initially 
observed in the dosage trial, which only looked at 24 hours post-injection. This included the up-
regulation of type-I IFNs, IFN-β (Figure 9B; p=0.0005) which had significant levels of induction 
as early as 3 hours post-injection and IFN-α (Figure 9A; p˂0.0001) which was not observed in 
the dosage trial as it is expressed at early time points with a significant increase of fold change at 
6 hours post-injection. Type-II interferon IFN-ɣ (Figure 9C; p=0.05) was also up-regulated at 6 
hours post-injection. At early time points we were also able to observe an increase in gene 
activity related to immune cell recruitment (Figure 9 H-L), indicating that RNA-LZ-1 utilizes 
immune cells to mount an immune response early on. For MIP-1α (Figure 9H; p˂0.0001), MCP-
1 (Figure 9I; p=0.001), RANTES (Figure 9J; p=0.0005), and IP-10 (Figure 9L; p˂0.0001) 
significant induction of gene regulation was observed at 6 hours post-injection with the up-
regulation turned off by 24 hours post-injection. Whereas MIP-2, which is also involved in 
immune cell recruitment, was up-regulated at 24 hours post-injection (Figure 9K; p=0.05). Pro-
inflammatory cytokines IL-6 (Figure 9D; p=0.001) and IL-18 (Figure 9E; p˂0.0001) were 
induced at 6 hours post-injection. The kinetics of IL-10 (Figure 9F; p=0.001) the anti-
inflammatory cytokine, which is known to turn off  the Th1 response (Berger, 2000), was 
significantly up-regulated at 6 hours post-injection. This induction of IL-10 may be responsible 
for the dissipation of immune response by 48 hours post-injection. Overall, we showed that 
RNA-LZ-1 is capable of inducing a potent immune response as early as 3 hours post-injection 
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with the effects on gene regulation dissipating by 48 hours post-injection. The fact that the 
immune response lasts only 24 hours could be beneficial in reducing the incidence of cytokine 
storms, which could be detrimental to the host, when paired with an antigen. 
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Figure 9: Kinetics of cytokines, chemokines, and interferons induced by RNA-LZ-1 in vivo. 
Six-week-old BALB/c female mice were injected intra-muscularly with either 5 µg of RNA-LZ-
1 or the control. At 3, 6, and 24 hours post-injection the injection site tissue was collected. Total 
RNA was extracted from the semi-membranous muscle using the TRIzol method. 500 ng of total 
RNA was used for reverse transcription into cDNA by the oligo(dT) primer. Cytokine and 
chemokine expression levels were detected using real-time PCR with gene-specific primers. The 
mRNA fold change was determined using the ΔΔCT method and normalized against the CT 
values of the housekeeping gene GAPDH. Statistical analysis was done using a two-way 
ANOVA for each cytokine (* p=0.05, ** p= 0.001, *** p=0.0005, **** p<0.0001). 
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4.3.3 Kinetics of immune response genes induced by VIDO’s triple adjuvant and the 
modified triple adjuvant  
Along with looking at the kinetics of RNA-LZ-1 we wanted to compare our results to a 
proven adjuvant. VIDO’s triple adjuvant has been successfully used as an adjuvant previously 
(Garg et al., 2014). Since polyI:C, a known RIG-I agonist, is a component of the triple adjuvant 
we also wanted to see the response if RNA-LZ-1 replaced polyI:C in the formulation. We 
expected that the replacement of polyI:C with RNA-LZ-1, modified triple adjuvant, would lead 
to a similar or beneficial response in inflammatory gene expression. For this animal trial we only 
looked at 6 and 24 hours post-injection. Similar with our previous trials the injection site, semi-
membranous muscle, was collected and gene response was evaluated using real-time qPCR.  
Like we expected VIDO’s triple adjuvant was a strong inducer of gene expression for a 
broad number of inflammatory related cytokines, chemokines, and interferons. However, in 
comparison to RNA-LZ-1 alone the triple adjuvant tended to up-regulate genes early on and 
return to basal levels of expression by 24 hours post-injection (Figure 10). Inflammatory 
cytokine genes IL-12β (Figure 10F; p˂0.0001), TNF-α (Figure 10G; p=0.05), IL-18 (Figure 10H; 
p=0.001), and IL-6 (Figure 10I; p=0.001) were all significantly up-regulated at 6 hours post-
injection with the fold change returning to basal levels by 24 hours post-injection. However, for 
IL-1β and IL-12α there was no significant increase in gene expression seen at either time point. 
The induction of early gene expression was also observed in type-I IFN IFN-α (Figure 10B; 
p=0.0005) and type-II IFN IFN-ɣ (Figure 10A; p˂0.0001). For type-I IFN IFN-β (Figure 10C; 
p=0.001) a constant significant increase of gene expression in comparison to the mock was 
observed at both 6 and 24 hours post-injection, it would be interesting to know whether this IFN 
response dissipates by 48 hours as it did in the case of RNA-LZ-1. Like RNA-LZ-1 VIDO’s 
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triple adjuvant induced a wide variety of chemokines involved in attracting immune cells (Figure 
10 J-O). Like the other genes tested the majority of immune cell recruiting genes were 
significantly up-regulated early on and shut off by 24 hours post-injection. These included KC-
GRO (Figure 10J; p=0.001), IP-10 (Figure 10L; p˂0.0001), MCP-1 (Figure 10M; p˂0.0001), and 
eotaxin (Figure 10O; p˂0.0001). For MIP-2 there appeared to be induction at 6 hours post-
injection, however, it was not significant (Figure 10K). MIP-1α showed up-regulation at both 6 
and 24 hours post-injection although the significance was less at 24 hours (Figure 10N; 
p˂0.0001; p=0.05). VIDO’s triple adjuvant showed to be a potent inducer of inflammatory 
cytokines, chemokines, and interferons as is expected by a proven adjuvant.   
Unlike what was expected, the modified triple adjuvant appeared to have a detrimental 
effect in comparison to VIDO’s triple adjuvant. In this case the addition of RNA-LZ-1 to the 
peptide and EP3 decreased the gene regulation effect seen when polyI:C is used in the traditional 
combination. This was surprising since RNA-LZ-1 is capable of inducing high expression alone 
in vivo and in our in vitro studies produced more IFN-β and inflammatory cytokines than 
polyI:C. Only in the case of IL-1β (Figure 10D; p˂0.0001) and KC-GRO (Figure 10J; p˂0.0001) 
at 24 hours post-injection did we see up-regulation of the genes by the modified triple adjuvant.  
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Figure 10: Kinetics of cytokines, chemokines, and interferons induced by the triple 
adjuvant and modified triple adjuvant in vivo. Six-week-old female BALB/c mice were 
injected intramuscularly with wither the triple adjuvant, the modified triple adjuvant, or 
phosphate buffered saline. At six and twenty-four hours post-injection mice were euthanized and 
the semi-membranous muscle from both hind legs was collected. The total RNA was extracted 
from the tissue using the TRIzol method. 500 ng of total RNA was used to make cDNA using 
reverse transcription and the oligo(dT) primer. Cytokine, chemokine, and interferon mRNA 
expression levels were detected using real-time PCR with gene specific primers. The mRNA fold 
change levels were determined using the ΔΔCT method and normalized against the CT values of 
the housekeeping gene GAPDH. Statistical analysis was done using a two-way ANOVA for each 
cytokine (* p=0.05, ** p= 0.001, *** p=0.0005, **** p<0.0001). 
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4.4 Discussion 
RNA-LZ-1 proved to be as potent in vivo as it was in vitro. Through a dosage trial we 
determined that a concentration of 5 µg of RNA-LZ-1 was most effective due to its ability to up-
regulate a multitude of immune response related genes. Similar to our cell culture work RNA-
LZ-1 induced high levels of IFN-β, which is the expected result of a RIG-I agonist. We also 
determined that the onset of up-regulation of IFN-β occurs early on after injection and slowly 
dissipates by 48 hours. Type-I IFN IFN-β is not the only interferon up-regulated by RNA-LZ-1, 
IFN-α another type-I IFN and IFN-ɣ the only type-II IFN were also up-regulated. IFN-α aids in 
the anti-viral immune response by enhancing the responses of natural killer cells and virus-
specific CD8+ T-cells (Cha et al., 2014). IFN-ɣ plays a major role in defining a Th1 immune 
response along with IL-12 (Schroder, Hertzog, Ravasi, & Hume, 2004), which were up-regulated 
by RNA-LZ-1 as well. The effects of IFN-ɣ include increasing the efficiency of both MSC class 
I and II antigen presentation and aiding in the maturation of T-cells, B-cells, and macrophage 
activation (Schroder et al., 2004). Since IFNs play an important role in innate and adaptive 
immune response, including antigen presentation, it is important to have an IFN response by 
adjuvants. VIDO’s triple adjuvant also induced a strong IFN response like RNA-LZ-1, however, 
the modified triple adjuvant was unable to produce up-regulation of any IFN.  
Induction of genes related to immune cell recruitment was also observed in both RNA-
LZ-1 and VIDO’s triple adjuvant treated groups. This is important in mounting an efficient 
immune response against pathogens by the host. Based on our kinetics studies both RNA-LZ-1 
and VIDO’s triple adjuvant were capable of inducing a robust local immune response in a mouse 
model. This allows us to be more confident in our results indicating that RNA-LZ-1 will be an 
effective adjuvant based on its ability to induce a broad spectrum of cytokines, chemokines, and 
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interferons. Moving forwards RNA-LZ-1 and VIDO’s triple adjuvant will be paired with 
antigens to evaluate antigen specific immune response.  
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Chapter 5 RNA-LZ-1 produces a robust immune response 
indicating potential as an adjuvant 
5.1 Rational 
RNA-LZ-1 induced significant levels of cytokines, chemokines, and interferons 
important in immune response at a concentration of 5 µg in an in vivo mouse model. When 
injected intra-muscularly into the semi-membranous muscle up-regulation of immune genes was 
observed at 3 hours post-injection with the genes returning to basal expression levels by 48 hours 
post-injection. As a positive control an adjuvant, which has proven to aid in protection against 
virus challenge, was used as a comparison for the gene profile. RNA-LZ-1 showed similar up-
regulation of immune genes to VIDOs triple adjuvant. Therefore, moving forwards both RNA-
LZ-1 and VIDOs triple adjuvant will be paired with antigens against avian influenza A viruses. 
Chapter 6 presents the results from the vaccine trial, which will show whether RNA-LZ-1 has the 
potential to be an effective adjuvant.  
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Chapter 6 Inactivated H5N1 and H7N9 vaccines against specified 
avian influenza A virus strains 
6.1 Introduction 
Influenza A virus is an important pathogen that causes disease in a wide variety of 
species, including swine, avian, and human leading to economic loss in the pork and poultry 
industries and added burden on our health care systems. In order to meet the growing risk of 
pandemic influenza viruses, there is a demand to create more effective and immunogenic 
vaccines. Recently, outbreaks of avian influenza viruses in the human population have added to 
this growing risk. Therefore, strategies to address the demands of higher efficiency, 
immunogenicity, and safety must be explored. One strategy, which addresses efficiency and 
immunogenicity, is to explore the addition of an adjuvant to influenza vaccines. Currently the 
Food and Drug Administration (FDA) has approved an oil in water emulsion (ASO3) adjuvanted 
H5N1 vaccine for national stock pile in the United States (Cao et al., 2016). This ASO3 adjuvant 
has also previously been paired with the pandemic H1N1 vaccine, however, children and adults 
vaccinated with this showed side effects including narcolepsy (Cao et al., 2016). Therefore, there 
is a need to explore other adjuvant options relating to influenza vaccines specifically. 
In our previous objectives, we have shown that RNA-LZ-1 is a strong adjuvant candidate. 
Since RNA-LZ-1 was able to induce broad spectrum immune response we believe that it will 
increase the immune response against a paired antigen. In this final objective we look to evaluate 
the antigen-specific antibody response of animals vaccinated with either the inactivated viruses 
alone or paired with one of the following adjuvants, RNA-LZ-1 and VIDO’s triple adjuvant. 
Animals were given prime and boost vaccination two weeks apart and sacrificed 10 days post-
boost to evaluate the antibody response. Serum was collected prior to each vaccination so that we 
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could evaluate the difference between a single or double dose of the vaccines. We hypothesize 
that the addition of RNA-LZ-1 will increase the antigen-specific antibody response in 
comparison to the inactivated virus alone.  
6.2 Materials and methods 
6.2.1 Propagation and inactivation of virus 
The following work was done in containment level 3 at VIDO-InterVac, including plaque 
assay and inactivation described later on. MDCK cells were grown in T150 flasks to confluency. 
Both A/Alberta/01/2014 H5N1 and A/BC/01/2015 H7N9 viruses, provided by the National 
Microbiology Laboratory in Winnipeg, Manitoba, were infected at a multiplicity of infection 
(MOI) of 0.001, and the virus inoculum was incubated on the cells for 1 hour at 37°C with 5% 
CO2. The cells were then rinsed and viral growth media, basal minimum essential medium eagle 
(Sigma, RNBF4696) with 0.25% BSA (Sigma, A7906-100g) and 1 µg/ml TPCK trypsin 
(Affymetrix, 9002-07-7), was added to the cells. Cells were then incubated for 48 hours at 37°C 
with 5% CO2, which is the length of time needed to see 100% cytopathic effect. At this point the 
supernatant was harvested and spun down briefly to remove any cell debris. β-propiolactone 
(Sigma-Aldrich, P5648) was added at a dilution of 1:2000 to the viral supernatant for 
inactivation. The viral supernatant was then incubated overnight with the β-propiolactone, 
rocking at 4°C. Once the inactivation procedure was complete it was stored at -80°C. 
6.2.2 Plaque assay 
A plaque assay was done to confirm that inactivation with β-propiolactone was successful 
and to determine the virus titre prior to inactivation. For inactivation confirmation MDCK cells 
in a 6-well plate, in duplicate, were infected with a 1 in 100 dilution of inactivated virus or mock 
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infected. To determine virus titre MDCK cells were plated in 6-well plates and the cells were 
infected with 10-5, 10-6, and 10-7 dilutions of each virus in duplicate. Plates were  
Incubated for one hour with the inoculum at 37°C with 5% CO2. Agar mixed with viral growth 
media was then added to the cells after the inoculum was removed and let stand for ten minutes 
until the agar started to solidify. Plates were then placed in the incubator for 48 hours at 37°C 
with 5% CO2. After incubation the agar is removed and coomassie blue is added to the cells for 
ten minutes. The coomassie blue is then rinsed off with reverse osmosis treated water and the 
plate can be left to dry on paper towel. After drying the plate can be examined for plaques. 
6.2.3 Virus purification 
Once the viruses were confirmed inactivated they were decontaminated out of the CL3 
laboratory using proper disinfectant, microchem plus (National Chemical Laboratory Inc., 0255) 
with a 10-minute contact time, and brought to the CL2 laboratory for purification. Purification 
was done using ultra-centrifugation with a sucrose gradient. First the inactivated viral 
supernatant is ultra-centrifuged at 25000 rpm for 2 hours and 30 minutes at 4°C to form a pellet 
of un-purified virus. The supernatant of the pelleted virus is removed and 1 ml of TSE buffer 
(0.02 M Tris, 0.15 M NaCL, and 0.002 M EDTA-Na in ddH2O) is added. The pellet is then left 
overnight at 4°C to allow for it to soften. The next day you make a sucrose gradient using 60% 
and 30% sucrose in TSE buffer, with the 30% sucrose layered on top of the 60% sucrose. The 
virus pellet is then re-suspended and added to the top of the sucrose gradient. The virus and 
sucrose gradient are then centrifuged at 25000 rpm for 2 hours and 30 minutes at 4°C. Purified 
virus can then be visualized at the sucrose/sucrose interface and is removed using a 2 ml plastic 
pipette and moved to a new tube. TSE buffer is added to the purified virus to wash and remove 
any residual sucrose from the sample and then ultra-centrifuged for 1 hour 30 minutes at 35000 
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rpm, 4°C. The supernatant is then removed and 0.5 ml TSE buffer is added to the pellet and it is 
left overnight at 4°C to soften. The next day the pellet is re-suspended in TSE buffer and 
additional TSE buffer is used to wash the walls of the tube, total volume around 1.5 ml. The 
purified virus can then be aliquoted out and stored at -80°C.  
6.2.4 Ethics statement 
In accordance with the Guidelines of the Canadian Council on Animal Care and with 
the University of Saskatchewan Committee on Animal Care and Supply all animals were treated 
and cared for in compliance with the 3R principles at VIDO-InterVac, University of 
Saskatchewan. The following experiment was approved by the University of Saskatchewan 
Animal Ethics Board. 
6.2.5 Vaccine mouse trial 
Thirty-five six-week-old naïve female BALB/c mice were used in this study. Animals 
were divided randomly into seven groups of 5 animals. The groups are as follows; PBS control 
group, inactivated H5N1 vaccine, inactivated H7N9 vaccine, inactivated H5N1 vaccine plus 
RNA-LZ-1, inactivated H7N9 vaccine plus RNA-LZ-1, inactivated H5N1 vaccine plus VIDO 
triple adjuvant, and inactivated H7N9 vaccine plus VIDO’s triple adjuvant. Similar with previous 
trials RNA-LZ-1 was complexed with in-vivo jetPEI to reduce degradation once injected and 5 
µg of RNA-LZ-1 was injected per mouse. For both of the antigens 1 µg of HA protein was used 
per mouse. On day 0 after 7 days of acclimation animals were pre-bled and then injected intra-
muscularly with 25 µl of vaccine per leg into the semi-membranous muscle. Fourteen days after 
the first injection animals were bled for serum and then given a booster of the same vaccination. 
Ten days after the boost animals were bled and sacrificed.   
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6.2.6 Hemagglutinin inhibition assay 
Serum from the vaccinated animals was treated with receptor destroying enzyme (RDE) 
(Sigma-Aldrich, C8772), diluted 1 in 20 in calcium saline pH 7.2, and incubated overnight at 
37°C. The next day 1.5% sodium citrate was added to the serum and the mixture was incubated 
at 56°C for 30 minutes to inactivate the RDE. Next the serum is treated for 1 hour at 4°C with 
50% red blood cells (RBC) from chicken to reduce nonspecific agglutinations. When the 
incubation period was over tubes were briefly centrifuged and cleared serum was moved to a 
new tube. The serum is now ready to be used for the assay. 
In a 96-well plate serum samples were serially diluted 2-fold through wells A-H. 
Standardized antigen, 4 HA units of the designated virus, was added to every well. The serum 
and standardized antigen were allowed to incubate together for 1 hour at room temperature. After 
the incubation time 1% RBCs were added to every well and the plate was observed after 30 
minutes incubation at room temperature for the formation of buttons. Formation of a button, the 
RBCs pooled at the bottom of the well, indicates that the serum has enough antibodies present to 
inhibit the hemagglutination by the virus.  
In a 96-well plate serum samples were serially diluted through wells A-H. Standardized 
antigen, 4 HA units of the designated virus, was added to every well. The serum and 
standardized antigen were allowed to incubate together for 1 hour at room temperature. After the 
incubation time 1% RBCs were added to every well and the plate was observed after 30 minutes 
incubation at room temperature for the formation of buttons. Formation of a button indicates that 
the serum has enough antibodies present to inhibit the hemagglutination by the virus.  
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6.2.7 IgG antigen-specific ELISA 
The day before the assay was performed a 96-well plate is coated with 2.5 µg/ml of 
antigen, either inactivated H5N1 or H7N9 virus, in coating buffer (0.015 M NaCO3, 0.035 M 
NaHCO3 in ddH2O, pH 9.6) and left at 4°C overnight. The coating antigen was then removed 
from the plate and the plate was washed 4 times in 1xTBST (0.1 M Tris, 0.17 M NaCl, 0.05% 
Tween 20 in ddH2O) before blocking buffer (1% skim milk in 1 × TBST) was added to the plate 
and incubated for 1 hour at room temperature. After blocking the plate was washed again 4 times 
and then the serum samples were added. In the first well a 1 in 40 dilution of serum was added, 
the serum was then serially diluted 4 times down the rows (wells A – H) in 0.5% skim milk in 1 
× TBST. The serum was then incubated on the plate for 1.5 hours at room temperature. After 
washing the plate a 1 in 5000 dilution of phosphatase labeled reserveAP anti-mouse IgG 
antibody (KPL, 0751-1806) in 0.5% skim milk in 1 × TBST was added to all wells and allowed 
to incubate at room temperature for 1 hour. Finally, PNPP substrate diluted 100 times in PNPP 
buffer (1% diethanolamine, 0.5 mM MgCl2 in ddH2O) was added to develop the plates. After 20 
minutes of incubation at room temperature the plates were read at 405 nm with a 490 nm 
reference filter.  
6.2.8 Statistical analysis  
Statistical analysis was done using a two way ANOVA with multiple comparison 
between each time point to the designated mock group in GraphPad Prism software. 
6.3 Results 
6.3.1 Ability of RNA-LZ-1 to produce an H5N1-specific antibody response 
For this experiment, we paired RNA-LZ-1 and VIDO’s triple adjuvant with two 
different antigens, inactivated H5N1 and H7N9 avian influenza A viruses. The H5N1 inactivated 
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whole virus had low immunogenicity on its own (Figure 11) so the addition of an adjuvant was 
essential in producing protective antibodies. The addition of either RNA-LZ-1 or the triple 
adjuvant significantly increased both antigen-specific IgG antibodies (Figure 11A) and 
neutralizing antibodies (Figure 11B) after one or two doses of the vaccines. Both the IgG titre 
and hemagglutinin inhibition (HAI) titre showed us similar patterns indicating strength in our 
results. After the prime vaccination antigen-specific antibodies were not significantly induced 
compared to the mock group for either RNA-LZ-1 or VIDO triple adjuvant paired groups. 
However, after both the prime and boost vaccination both groups adjuvanted with either RNA-
LZ-1 (Figure 11B; p=0.05) or VIDO’s triple adjuvant (Figure 11B; p˂0.0001) had significantly 
increased H5N1-specific IgG titres. For HAI, RNA-LZ-1 significantly induced the titre in 
comparison to the mock after both prime and boost vaccinations (Figure 11B; p˂0.0001). This 
result was also seen for the VIDO triple adjuvant paired H5N1 group (Figure 11B; p˂0.0001). 
Classically for the HAI assay, a hallmark assay of influenza vaccine protection, a titre ≥40 was 
considered protective (Baz, Luke, Cheng, Jin, & Subbarao, 2013; Sun et al., 2017), however, 
recently for H5N1 specifically it has been shown that HAI titres as low as 10 or 20 are sufficient 
to provide protection against challenge (Mahmood et al., 2008; Pearce et al., 2012). Based on 
these reports we can state that RNA-LZ-1 when paired with an H5N1 antigen is capable of 
producing protective HAI antibody titres. RNA-LZ-1 when compared to VIDO’s triple adjuvant 
can be said to be just as efficient at producing antigen-specific antibodies. These results indicate 
that RNA-LZ-1 has the potential to be an effective adjuvant when paired with vaccines against 
H5N1 avian influenza A virus strains.     
 
 
59	
	
 
 
Figure 11: Vaccination with inactivated H5N1 influenza virus paired with an adjuvant led 
to an increased antibody response. Serum was collected from animals at three different time 
points, prior to vaccination and at necropsy (n=5). Plates were coated with H5N1 antigen and 
goat anti-mouse IgG antibody was used to detect antigen specific IgG (A). Serum was serially 
diluted and H5N1 virus was added to determine the titre of hemagglutinin inhibition (B). 
Statistical analysis was done using a two-way ANOVA (* p=0.05, **** p<0.0001). 
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6.3.2. Ability of RNA-LZ-1 to induce H7N9-specific antibody response 
Compared to our H5N1 results (Figure 11) the vaccine combinations against H7N9 
proved to have an unexpected result. Unlike the H5N1 strain H7N9 can be fairly immunogenic 
on its own. In the case of our trial the H7N9 inactivated whole virus alone was capable of 
inducing an IgG titre (Figure 12A; p=0.05) and protective HAI titres after the boost vaccination 
(Figure 12B; p=0.001). The addition of VIDO’s triple adjuvant led to the expected results of 
significantly increased antigen-specific IgG titres (Figure 12A; p˂0.0001) and producing a 
protective HAI titre (Figure 12B; p˂0.0001). However, unlike what we expected the addition of 
RNA-LZ-1 as an adjuvant appeared to have a negative effect on the antigen-specific antibody 
titres. For the HAI titres (Figure 12B) even though the RNA-LZ-1 group had protective antibody 
levels ≥40 in relation to the H7N9 inactivated virus alone it was not more protective. This pattern 
of results can also be observed in the antigen-specific IgG titres (Figure 12A). After comparing 
the RNA-LZ-1 adjuvanted H7N9 group to the previous H5N1 group it leads to questions about 
the results seen in Figure 12. One case may be that since H7N9 alone is so immunogenic the 
addition of RNA-LZ-1 led to a cytokine storm, an excessive release of pro-inflammatory 
cytokines, decreasing the induction of antigen-specific antibodies. Another factor could be the 
length of time between the prime and boost vaccinations. In our case there was a 2 week spread 
between vaccinations, if the time between the 2 vaccinations was increased it may allow the 
immune response to dip back down to basal levels before peaking with the boost vaccination. 
Instead it is possible that the immune response in the mice was still decreasing when the booster 
was given, leading to a heightened response and possible cytokine storm.  
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Figure 12: Vaccination with inactivated H7N9 influenza virus paired with the triple 
adjuvant led to an increased antibody response. Serum was collected from animals at three 
different time points, prior to vaccination and at necropsy (n=5). Plates were coated with H7N9 
antigen and goat anti-mouse IgG antibody was used to detect antigen specific IgG (A). Serum 
was serially diluted and H7N9 virus was added to determine the titre of hemagglutinin inhibition 
(B). Statistical analysis was done using a two-way ANOVA (* p=0.05, ** p= 0.001, **** 
p<0.0001). 
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6.4 Discussion 
Vaccination for H5N1 with RNA-LZ-1 as an adjuvant led to a significantly increased 
antigen-specific antibody production. This result proved that RNA-LZ-1 has the potential to be a 
potent adjuvant against RNA viruses. In comparison to VIDO’s triple adjuvant RNA-LZ-1 
significantly increased antibody titres to similar levels against H5N1. Over the last couple years 
avian H5N1 has become a pandemic threat due to its high level of mortality in humans directly 
infected from poultry, and due to the fact that influenza mutates so rapidly it may soon achieve 
sufficient transmissions in humans (Webster & Govorkova, 2006). Therefore, the fact that RNA-
LZ-1 was able to significantly increase antibody responses and that the mechanism of action is 
known makes RNA-LZ-1 a candidate for future testing as an adjuvant. Since there was no 
challenge study in these results, due to regulatory factors, it is imperative to perform a challenge 
study to solidify RNA-LZ-1 efficacy as an adjuvant candidate.  
For H7N9 vaccination it was found that VIDO’s triple adjuvant was able to significantly 
increase antibody response compared to the un-adjuvanted vaccine. In comparison, the addition 
of RNA-LZ-1 was detrimental on the antibody protection induced by a prime boost vaccination 
regime. This half of the trial will need to be repeated in order to confirm whether our results 
were correct and RNA-LZ-1 is downregulating the antibody response or if there is a secondary 
reason why this result was observed. Whether a cytokine storm is being produced or there needs 
to be increased time between the prime and boost vaccinations.  
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Chapter 7 Discussion and conclusions 
Currently there is a significant need for vaccines, which are highly immunogenic and 
have a strong safety profile. A major strategy for enhancing immunogenicity is the addition of an 
adjuvant. Recently more experimental adjuvants acting on pattern recognition receptors (PRR) 
have been discovered. Many viruses trigger different PRRs, which lead to not only the inhibition 
of the virus but also to the development of an adaptive immune response (Martinez-Gil et al., 
2013). These adjuvants which act on the PRRs utilize this phenomenon triggering a similar 
immune response to that of natural infection via the viruses. Common PRRs targeted by 
adjuvants being developed are toll like receptors (TLR) and RIG-I like receptors (RLR). 
Adjuvants targeting TLR pathway activation include; TLR4 by AS03 (Alving et al., 2012), 
TLR9 by CpG (Hemmi et al., 2000), and TLR3 by polyI:C (Ishii, Koyama, Nakagawa, Coban, & 
Akira, 2008). The activation of RLRs by experimental adjuvants include; polyI:C activating 
MDA5 (Ishii et al., 2008), copy back defective interfering RNA derived from Sendai virus and 
RIG-I (Martinez-Gil et al., 2013), microRNA-136 and RIG-I (Zhao et al., 2015), M8 and RIG-I 
(Beljanski et al., 2015), 3pRNA and RIG-I (Hochheiser et al., 2016), and RNAdjuvant and RIG-I 
(Ziegler et al., 2017). Since the stimulation of these PRRs mimic natural infection the signals 
produced can directly or indirectly increase the presence of antigen-presenting cells (APCs) 
through cytokine and chemokine induction (Desmet & Ishii, 2012), therefore, increasing the 
adaptive immunity to the paired antigen. This type of adjuvant tends to produce a Th1 skewed 
response due to the induction of pro-inflammatory cytokines and will be beneficial to vaccines 
against pathogens requiring a cell-mediated immune response, such as influenza A (Beljai et al., 
2015; Ziegler et al., 2017). Therefore, this study determined whether a new small RNA 
molecule, RNA-LZ-1, which binds to the cytosolic receptor RIG-I was capable of inducing a 
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broad spectrum immune response and lead to protective antibody response to a paired antigen 
against influenza A virus.  
Previously in our laboratory it was determined that the panhandle structure derived from 
the 3’ and 5’ non-coding regions of the influenza A genome, which is highly conserved, had a 
strong binding affinity for RIG-I (G. Liu et al., 2015). We opted to explore whether this small 
RNA molecule, RNA-LZ-1, was capable of becoming a prospective adjuvant. Based on previous 
research of RIG-I agonists showing increased protection in mice challenged with RNA viruses 
(Beljanski et al., 2015; Cao et al., 2016; Hochheiser et al., 2016; Martinez-Gil et al., 2013; 
Ziegler et al., 2017) we expected that our RIG-I agonist would be a potent inducer of 
inflammatory immune response and lead to protective antibodies against a paired antigen. We 
first confirmed in vitro that RNA-LZ-1 was indeed inducing the RIG-I pathway. Human 
macrophages and lung epithelial cells were transfected with RNA-LZ-1 or the known RIG-I 
inducer, polyI:C, and supernatant and cell lysis were collected 18 hours after transfection. ELISA 
and qPCR were used to analyze IFN-β at the protein and mRNA level respectively. As expected 
RNA-LZ-1 was capable of inducing significant levels of expression higher than or equal to that 
of polyI:C. At the protein level we also determined that RNA-LZ-1 was capable of inducing 
inflammatory cytokines in transfected cells. RNA-LZ-1 was confirmed to be a potent inducer of 
type-I IFNs due to its ability to stimulate a more robust immune response in comparison to 
polyI:C. Previous results with the M8 RIG-I agonist derived from vesicular stomatitis virus, 
which was proven to be protective in a mouse model, showed induction in vitro of both IFN-β 
and IL-6 similar to RNA-LZ-1 (Chiang et al., 2015). Therefore, due to the similarity in in vitro 
responses between M8 and RNA-LZ-1 we could justify moving into an in vivo mouse model to 
test whether this robust immune response detected in cell culture could be replicated in vivo. 
65	
	
As suspected, in vivo RNA-LZ-1 was able to induce a broad spectrum immune response 
in injection site tissue. Since RNA-LZ-1 has never been tested in the mouse model it was 
important to determine the optimal dose for immune response induction. Based on previous 
research with a RIG-I agonist (Beljanski et al., 2015) we chose our dosage range to be 1 µg, 2.5 
µg, and 5 µg. The 5 µg dose of RNA-LZ-1 was the most proficient inducer of inflammatory 
genes, 5 µg was the same concentration used in previous studies in BALB/c mice with a RIG-I 
agonist derived from vesicular stomatitis virus (Beljanski et al., 2015). An up-regulation of IFN-
β, pro-inflammatory cytokines, and immune cell recruitment genes were observed, indicating 
that the optimal dose in vivo was 5 µg of RNA-LZ-1. The resulting inflammatory gene profile 
suggested a skewed Th1 response. The next logical step was to determine the kinetics of RNA-
LZ-1 in vivo to profile the immune response. RNA-LZ-1 induced an immune response early on 
post-injection dissipating by 48 hours. The majority of genes were up-regulated at 6 hours post-
injection and returned to basal levels by 24 to 48 hours post-injection. Due to this pattern many 
genes not up-regulated during the dosage trial were observed in the kinetics trial. The majority of 
genes found to be up-regulated by RNA-LZ-1 in vivo have been previously characterized as 
genes differentially expressed by RIG-I (Goulet et al., 2013). Based on the previous analysis 
(Goulet et al., 2013) we can conclude that RNA-LZ-1 up-regulates genes in the following 
functional categories; chemokines, type-I IFN, and pro-inflammatory cytokines. In future studies 
it would be beneficial to check genes related to the activation of the NF-κB pathway and IFN 
regulatory factor signalling, however, based on the downstream production of IFNs, cytokines, 
and chemokines we can suspect that these pathways are being activated. The genes up-regulated 
by RNA-LZ-1 through the RIG-I pathway indicate a skewed Th1 immune response, leading to 
the clearance of intracellular pathogens, however, over stimulation of pro-inflammatory 
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cytokines can have a negative effect on the host cells (Berger, 2000). To prevent an excessive 
cytokine response, or cytokine storm, the body has a mechanism to regulate this response, hence 
the Th2 immune response. Th2 immune response produces many cytokines and interleukins 
important for antibody production and eosinophil activation, however, it also produces the anti-
inflammatory cytokine IL-10 which is capable of counteracting the Th1 response (Berger, 2000). 
At 6 hours post-injection we see a spike in IL-10 up-regulation, this may be activated in order to 
control the Th1 response and not cause a cytokine storm. Based on the promising gene profile 
collected from the kinetics trial we wanted to compare our results to the gene profile of a known 
adjuvant.  
VIDO’s triple adjuvant has been shown to increase the efficacy of a subunit vaccine 
against respiratory syncytial virus (Garg et al., 2014). Following the same procedure as the 
RNA-LZ-1 kinetics trial mice were injected intra-muscularly and tissue samples were collected 
at 6 and 24 hours post-injection. Similar to RNA-LZ-1 the triple adjuvant induced gene up-
regulation early on with regulation being shut down by 24 hours and basal levels of expression 
observed. There was significant overlap of genes up-regulated between RNA-LZ-1 and the triple 
adjuvant. As expected RNA-LZ-1 was able to induce inflammatory genes similar to that of a 
proven adjuvant, supporting our hypothesis that RNA-LZ-1 will be an effective adjuvant.  
Another RIG-I agonist is part of the triple adjuvant formulation, polyI:C, and made us 
question what effect RNA-LZ-1 might have when paired with the other components of the triple 
adjuvant, replacing polyI:C. For this injection RNA-LZ-1 was added at the same ratio as polyI:C 
to the other components and injected intra-muscularly. We expected the replacement of polyI:C 
with RNA-LZ-1 to induce similar levels of gene expression in comparison to the original triple 
adjuvant. However, that was not the case as the addition of RNA-LZ-1 had a detrimental effect 
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on gene up-regulation. All cytokines and chemokines directly linked to the RIG-I pathway were 
kept at basal levels. Initially we believed that the concentration of RNA-LZ-1 was too high, as 10 
µg was added to replicate the amount of polyI:C in VIDO’s triple adjuvant, as many paper 
utilizing RIG-I agonists worked with a maximum concentration of 5 µg per mouse (Beljanski et 
al., 2015; Hochheiser et al., 2016; Martinez-Gil et al., 2013). However, after searching the 
literature more, 3 papers were recovered, which utilized higher concentrations of RIG-I agonists 
without the negative response observed in our trial (Cao et al., 2016; Goulet et al., 2013; Ziegler 
et al., 2017). Although in all of these papers the RIG-I agonist was not complexed with other 
compounds, therefore, it is possible that the combination of peptide and EP3 with RNA-LZ-1 is 
not compatible. Based on these results only RNA-LZ-1 and VIDO’s triple adjuvant were 
continued with for the vaccine trial. 
In the host RIG-I is responsible for the detection of viruses from the following families 
orthomyxoviridae, paramyxoviridae, rhabdoviridae, and flaviviridae (Kato et al., 2006; Ranjith-
Kumar et al., 2009; Sumpter et al., 2005; Yoneyama et al., 2004). The host requires a cell-
mediated immune response in order to combat viruses from these families. In the case of cell-
mediated immunity a Th1 immune response is needed for the production of pro-inflammatory 
cytokines (Berger, 2000). Based on this knowledge we chose to pair RNA-LZ-1 with avian 
influenza A virus strains. The highly pathogenic avian influenza A strain H5N1 and the avian 
influenza A strain H7N9 have in recent years spilled over the species barrier to infect humans 
(Cao et al., 2016; Sun et al., 2017). Though these viruses cannot sustain efficient human to 
human transmission, human infections are occurring from direct contact with infected poultry 
(Uyeki, 2009). For this study whole virus was inactivated with β-propiolactone, which was used 
to inactivate whole virion pandemic H1N1 vaccines ("CSL H1N1 pandemic influenza vaccine," 
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2009). This trial compared the induction of antigen-specific antibodies between the inactivated 
whole virus with or without one of the two adjuvants, RNA-LZ-1 or VIDO’s triple adjuvant. 
Based on our previous trials we expected RNA-LZ-1 to induce antigen-specific antibodies 
comparable to that of VIDOs triple adjuvant. 
Animals received a prime boost vaccination regime, with two weeks between the 
vaccinations, and were sacrificed 10 days post-boost. Serum samples were collected prior to 
vaccinations and necropsy. Vaccination of inactivated H5N1 alone is known to have low 
antigenicity, as H5 is significantly less immunogenic compared to other hemagglutinin subtypes 
(Nicholson et al., 2001). The addition of an adjuvant is needed to jump this hurdle of low 
immunogenicity. We first did a hemagglutination inhibition assay, as it is the golden standard for 
determining antibody sero-protection for influenza A viruses. If the serum contains antibodies 
against the strain of interest it will prevent the virus from attaching to the RBCs, therefore, 
blocking hemagglutination. The general assumption is that an HAI titre ≥40 will provide at least 
a 50% reduction of influenza infection in humans (Potter & Oxford, 1979; Sun et al., 2017). The 
RNA-LZ-1 adjuvanted inactivated whole virus H5N1 vaccine was capable of producing an HAI 
titre of 40 after both the prime and boost vaccination. The vaccine adjuvanted with VIDO’s triple 
adjuvant showed similar results. In comparison, the un-adjuvanted H5N1 vaccine was unable to 
produce protective antibodies against the virus. At first a HAI titre only equal to 40 seemed low 
but other papers have reported that HAI titres ≥10 were capable of decreasing viral replication in 
ferrets infected with H5N2 (Baz et al., 2013; Pearce et al., 2012). It was also shown that the 
H5N1 vaccine stockpiled in the U.S. only produced HAI titres of 40 in a recent study, however, 
the vaccine was still able to provide protection (Sun et al., 2017). These observations paired with 
our results indicate that for the less immunogenic H5 strains HAI titres under 40 are still able to 
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provide protection. The matching antigen-specific IgG antibody titre data confirmed the results 
showing increased antibody titres for the adjuvanted vaccines increasing after each vaccination. 
As expected our results showed that RNA-LZ-1 was capable of inducing a protective antibody 
response to the paired antigen of inactivated whole virus H5N1.  
Vaccination with the inactivated H7N9 virus alone was capable of producing high levels 
of antigen-specific antibodies. In comparison to H5N1, H7N9 is highly immunogenic alone, 
however, the addition of VIDO’s triple adjuvant led to significantly increased titres. After each 
vaccination, the titres increased for the previous two groups. In comparison, the addition of 
RNA-LZ-1 as an adjuvant had detrimental effects on the antibody titres, producing both HAI and 
antigen-specific IgG titres lower than that of H7N9 alone. This result was surprising as we 
expected RNA-LZ-1 to have a positive effect on antibody titres. One possible cause for this 
result could be that due to H7N9’s immunogenicity alone the addition of RNA-LZ-1 led to a 
cytokine storm. This could have been aided by the shortened length of time between injections, 
as two weeks may have been too short for the immune response to return to basal levels before 
being stimulated again with the booster vaccination. However, the only way to figure out why 
this result occurred would be to repeat the trial. If this trail was to be repeated the length in time 
between prime and boost vaccination should be increased to a minimum of three weeks and a 
lower concentration of RNA-LZ-1 should be included to account for over stimulation of the 
cytokine response. Overall inactivated H7N9 whole virus with or without the addition of VIDO’s 
triple adjuvant were able to stimulate significantly increased levels of antigen-specific 
antibodies. 
This project was successful in proving the hypothesis correct. We showed that RNA-
LZ-1 produced a robust immune response both in vitro and in vivo and was capable of inducing 
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significant antigen-specific antibodies against the paired antigen, inactivated H5N1 virus. Based 
on the data presented RNA-LZ-1 has the potential to be an adjuvant used in vaccines against 
viruses, which naturally trigger the RIG-I pathway. The next step for defining RNA-LZ-1 as an 
adjuvant would be to do a challenge trial to show whether the antibodies observed are able to 
provide protection against homologous challenge. At this point in time that trial was not possible 
for us, due to the nature of highly pathogenic avian influenza A virus research and the protocols 
in place surrounding animal work. Moving forwards RNA-LZ-1 will have the advantage of an 
adjuvant with a known mechanism of action increasing the safety profile, as unlike adjuvants 
such as alum, we have the knowledge behind the induction of the immune response. 
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Appendix 
Table A1: Primers used for cytokine, chemokine, and interferon analysis by qPCR 
Target gene Direction Sequence 
IFNγ Forward 5' TCAAGTGGCATAGATGTGGAAGAA 3' 
Reverse 5' TGGCTCTGCAGGATTTTCATG 3' 
IFNα Forward 5' CCTGTGTGATGCAACAGGTC 3' 
Reverse 5' TCACTCCTCCTTGCTCAATC 3' 
IFNβ 
Forward 5' ATCATGAACAACAGGTGGATCCTCC 3' 
Reverse 5' TTCAAGTGGAGAGCAGTTGAG 3' 
CXCL10 (IP-10) Forward 5' ATGACGGGCCAGTGAGAATG 3' Reverse 5' GAGGCTCTCTGCTGTCCATC 3' 
CCL3 (MIP-1α) Forward 5' CTTCTCTGTACCATGACACTC 3' Reverse 5' AGGTCTCTTTGGAGTCAGCG 3' 
CCL2 (MCP-1) Forward 5' CTTCTGGGCCTGCTGTTCA 3' Reverse 5' CCAGCCTACTCATTGGGATCA 3' 
CXCL2 (MIP-2) 
Forward 5' TGCGCCCAGACAGAAGTCATAGC 3' 
Reverse 5' GCTCTAGAGTCAGTTAGCCTTGCCTTTG 3' 
CXCL1 (KC-GRO) Forward 5' ATGAGCTGCGCTGTCAGTGC 3' Reverse 5' CACCAGACGGTGCCATCAGA 3' 
IL-12α (p35) Forward 5' GGTGAAGACGGCCAGAGAAA 3' Reverse 5' GTAGCCAGGCAACTCTCGTT 3' 
IL-12β (p40) Forward 5' GACCCTGCCCATTGAACTGGC 3' 
Reverse 5' CAACGTTGCATCCTAGGATCG 3' 
TNFα Forward 5' AGGCACTCCCCCAAAAGATG 3' 
Reverse 5' CTGCCACAAGCAGGAATGAG 3' 
IL-1β 
Forward 5' GTGTGGATCCCAAGCAATAC 3' 
Reverse 5' GTCCTGACCACTGTTGTTTC 3' 
IL-18 Forward 5' TGGTTCCATGCTTTCTGGACTCCT 3' Reverse 5' TTCCTGGGCCAAGAGGAAGTGATT 3' 
IL-6 Forward 5' GTGGCTAAGGACCAAGACCA 3' Reverse 5' TAACGCACTAGGTTTGCCGA 3' 
IL-10 Forward 5' GCTGCCTGCTCTTACTGACT 3' Reverse 5' CTGGGAAGTGGGTGCAGTTA 3' 
CCL5 Forward 5' CTCACTGCAGCCGCCCTCTG 3' 
Reverse 5' CCTTGACGTGGGCACGAGGC 3' 
CCL11 Forward 5' AGAGGCTGAGATCCAAGCAG 3' 
Reverse 5' CAGATCTCTTTGCCCAACCT 3' 
β-actin Forward 5’ ACTGGGACGACATGGAG 3’ 
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Reverse 5’ GTAGATGGGCACAGTGTGGG 3’  
GAPDH Forward 5’ AACTTTGGCATTGTGGAAGG 3’  
Reverse 5’ ACACATTGGGGGTAGGAACA 3’  
HPRT 
Forward 5' GATTAGCGATGATGAACCAGGTT 3' 
Reverse 5' CCTCCCATCTCCTTCATGACA 3' 
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